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Abstract. 
Introduction: Early diagnosis represents the best opportunity for cure of gastro-intestinal 
cancers; however current gastro-intestinal cancer screening programmes have low test 
sensitivity and low patient acceptability. It is hoped that a better understanding of 
carcinogenesis and the development of new biomarkers will provide answers to these 
clinical problems.  
Hypothesis and aims: This thesis examines the current understanding of gastro-intestinal 
carcinogenesis focusing on colorectal and oesophageal cancers. It reviews the circulating 
gastro-intestinal cancer biomarker literature reporting the strengths, weaknesses and 
successes of current approaches. 
The study tests the hypothesis that control patients and patients with colorectal and 
oesophageal neoplasia have differing plasma levels and fragmentation patterns of cell free 
nuclear and mitochondrial DNA, and that endoscopic removal of these lesions returns the 
levels and patterns to normal. 
We aim to show how new techniques of DNA processing can improve results, and how the 
application of these results could form part of a diagnostic approach in an at risk 
population. We compare our results to and including carcinoembryonic antigen levels. 
Results: Cell free DNA was isolated from 164 patients, including 71 patients with 
oesophageal neoplasia, 50 patients with colorectal neoplasia, 35 patients without 
endoscopic abnormality and 8 patients with Barrett’s oesophagus.  
This is the first report of statistically significant differences in circulating DNA quantities and 
patterns in patients with early oesophageal and colorectal neoplasia (p≤ 0.005). Logistic 
regression of the best DNA marker for colorectal neoplasia demonstrated a ROC of 0.888, 
with a sensitivity of 81.1% and specificity of 75.8%. Logistic regression of the best DNA 
marker for oesophageal neoplasia demonstrated a ROC of 0.778 with a sensitivity of 81.3% 
and specificity of 60.5%. Carcinoembryonic antigen performed poorly with a ROC of 0.547 
and did not add diagnostically. There were no significant changes in markers from patients 
resected at endoscopy. 
Conclusions: These circulating markers in combination with other markers offer the 
prospect of a simple blood test as a possible screen for colorectal and oesophageal 
dysplasia and cancers in an at risk population.  
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Chapter 1 Gastro-intestinal cancers in the UK. 
1.1 Introduction. 
Gastro-intestinal carcinomas are some of the most common and rapidly increasing cancers 
in the United Kingdom (UK) and the western world1-3 (Figure 1). Societal costs are 
considerable with emotional, structural, and financial losses. 
The epithelial cells lining the bowel wall are the most usual sites affected, developing 
typically into squamous or adeno-carcinomas.  
Colorectal adenocarcinoma, the most common gastro-intestinal cancer and oesophageal 
adenocarcinoma, the most rapidly increasing cancer in the UK, are perhaps the two most 
important gastro-intestinal cancers of modern times. Twenty-three thousand six hundred 
and twenty-three people die from these two conditions in the UK each year (2010)2, and 
these are the focus of this thesis. 
 
Figure 1 -Top 20 cancers by incidence in the UK 2009. 
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1.2 Carcinogenesis theory. 
Current theory suggests that slow accumulation of random genetic and epigenetic 
aberrations, catalysed by carcinogens and inherited deoxy-ribonucleic acid (DNA) repair 
enzyme defects, lead to pro-cancerous expression of key genes. Eventually this results in a 
common cancer phenotype.  
Inherited genetic coding, environmental factors, inflammation (driving increased cellular 
replication), and the build up of errors from repeated genetic replication (ageing) effect the 
speed at which cancers develop, and reflect the age related incidence. 
1.2.1 Gene sequence changes. 
Genes promoting and supporting cellular growth (oncogenes), genes involved in cellular 
differentiation and shut down (tumour suppressors), and genes controlling cellular death 
(apoptosis) are present in all cells. Pro-cancerous mutations to these key genes and/ or 
epigenetic changes may produce uncontrolled proliferation signals. Similarly failure of 
tumour suppression and apoptosis pathways also result in uncontrolled proliferation. 
Neoplastic transformation often requires both. 
Primary genetic damage usually occurs through oxidation of DNA bases and itself may lead 
to failure of genetic expression. Secondary inaccurate repair of the damaged bases leads to 
mutations in the genetic sequence which may or may not alter gene expression. These 
changes occur throughout our lives and largely result in ageing, but at each stage neoplasia 
may result.  
  Gastro-intestinal cancers in the UK. 
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Increasing age and genetic damage may result in chromosomal instability (CIN). Loss of 
chromosomal areas (deletion) and multiplication of others (amplification) may occur 
increasing the rate of genetic change and increasing the risk of carcinoma development. 
Abnormal copy numbers of complete chromosomes (aneuploidy) may be seen in advanced 
neoplasia.  
1.2.2 Epigenetic changes. 
Changes promoting cancer are not restricted to genetic coding sequences. Epigenetic DNA 
changes allow modification of gene expression without change to the coding (genetic) 
region sequence. The most studied effect is at islands of relatively high Cytosine and 
Guanine base content (CpG islands) close to gene promoter regions. High levels of cytosine 
methylation (5-methylcytosine) in these CpG islands acts as a physiological gene silencing 
mechanism. Aberrant hypermethylation, and therefore silencing, of tumour suppressor and 
apoptotic genes are a frequently reported change in neoplasia progression.  
Hypomethylation of CpG sites is also seen in neoplasia, potentially releasing control of 
oncogenes, and by a different mechanism increasing susceptibility to DNA breaks (CIN)4.  
A less well studied epigenetic phenomenon, genetic imprinting, occurs when DNA 
methylation fixes genetic expression to a single predetermined parental allele. Loss of 
methylation and therefore imprinting of oncogenes may allow uncontrolled expression of 
the usually silent allele. 
1.2.3 Extra-genetic changes. 
Histone proteins act as structural scaffolding for DNA. They dictate the folding of DNA 
within chromatin influencing access to and expression of genes.  
  Gastro-intestinal cancers in the UK. 
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Epigenetic methylation, acetylation, and substitution of key amino acids in these proteins 
alter their structure changing gene accessibility and regulation which may favour 
expression of pro-cancerous genes5 (or repression of tumour suppressors).  
Stromal cells and the local extracellular matrix are also extra-genetic co-factors supporting 
the development of cancer6. Co-evolution of supporting cells7, and co-option of 
inflammatory cells to provide further local growth stimulus8 demonstrate the range of 
possible contributory factors combining to create the neoplastic environment. 
1.2.4 The metaplasia, dysplasia, carcinoma sequence. 
With increasing genetic damage gastro-intestinal lesions develop through common 
pathological stages:  Benign metaplasia (oesophageal cancer only – Barrett’s oesophagus), 
pre-cancerous dysplasia; carcinoma in situ; and finally invasive cancer. A carcinogenic 
process is required for neoplastic changes to develop but once invasive cancer has formed 
it is self sustaining. 
1.3 The Colon. 
The colon is lined by columnar-type epithelium, measuring approximately 150cm long, 
joining the small intestine to the anus. Its main function is to reabsorb water and control 
waste excretion. Anatomically it is divided into six parts; caecum and ileo-caecal valve; 
ascending colon; transverse colon; descending colon; sigmoid colon; and rectum. 
1.3.1 Polyp adenoma and carcinoma pathogenesis. 
A sequential morphological and pathological change from normal mucosa to adenoma with 
low (LGD) then high grade dysplasia (HGD), and finally carcinoma is recognised as the most 
common route for disease progression explaining 80% of cancers in the normal population9, 
10.   
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The proposed genetic model for this follows on from work by Fearon and Vogelstein11, with 
growth of abnormal epithelial cells from the  surface of the bowel mucosa into the 
glandular crypts.  
The initiating event is loss of the Wnt (Wingless and Int drosophila gene) pathway through 
APC dysfunction, often due to mutation, followed by further genetic loss and damage to 
onco- and tumour-suppressor genes eventually leading to cancer. 
Three central combinations have been associated with adenomas that progress to 
carcinoma: 17p loss (P53) and Kras mutation, 8q (C-MYC) and 13q (mir 17-92 cluster) gain, 
and 18q (DCC, SMAD4) loss and 20q (MMP9, SRC, TNFRSF6B) gain 12. However, although 
present they are not sufficient to initiate cancer, with further genetic change required. 
 
Figure 2 Adenoma pathways to cancer. 
 CIMP= CpG hypermethylation phenotype, MMR = mis-match repair gene, APC = adenoma Polyposis coli, DCC= 
deleted in colon cancer, P53 = protein 53, MSS = microsatellite stable, MSI = microsatellite instability, SMAD = 
mothers against decapentaplegic homolog, hMLH1 = human mutL homolog 1, P16(INK4) = cyclin dependent 
kinase inhibitor 2A, PTEN = phosphatase and tensin homolog.
13
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1.3.2 Serrated adenomas and Lynch syndrome. 
A subset of colorectal cancers has been characterized with deficient DNA mismatch repair 
linked to mutations of repair genes such as MSH2 (MutS Homolog 2), MSH6 (MutS 
Homolog 6), MLH1 (MutL Homolog 1), and PMS2 (post-meiotic segregation increased 2)14, 15. 
These mutations result in high frequency microsatellite instability (H-MSI), instability in the 
repeat number of usually highly conserved 1-6 bp DNA sequences present throughout the 
normal genome, reflecting defective DNA mis-match repair.  
Inherited defects of these genes lead to H-MSI Hereditary Non-Polyposis Colorectal Cancer 
or Lynch syndrome and account for 6% of all colon cancers16.   
Sporadic H-MSI is also found in 15-20% of colon cancers17, and sessile serrated adenomas 
are likely precursors. High levels of BRAF mutations, an oncogene similar to K-Ras, and 
aberrant DNA methylation are found in serrated adenomas and mirror the genotypical 
changes seen in sporadic H-MSI cancers18. 
1.4 The oesophagus. 
The oesophagus is lined by stratified squamous epithelium. Measuring 25 cm in length, the 
oesophagus joins the pharynx to the stomach, with an anatomical sphincter at its lower 
end. Its main function is to transmit food from the pharynx to the stomach, and prevent 
backwash of acid and stomach contents. 
1.4.1 Barrett’s oesophagus pathogenesis. 
Barrett’s oesophagus is a benign condition, involving metaplastic change of the epithelium. 
However, once Barrett’s oesophagus has developed the risk of adenocarcinoma increases 
by 30-150 folds.  Metaplastic change is not seen in colonic neoplasia.  
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Barrett’s oesophagus was first described in  195019  and involves replacement  of squamous 
epithelium with a specialised columnar epithelium, including intestinal-type mucosa. The 
development of Barrett’s oesophagus and adenocarcinoma is considered to be driven by 
reflux of acid and bile (refluxate) into the lower oesophagus. However, evidence for this is 
mainly epidemiological in humans, with gastro-oesophageal reflux linked to obesity.  
At a molecular level, caudal type homeobox 1 and 2 (CDX1, CDX2) expression are perhaps 
the only recognised pathogenetic molecular changes in Barrett’s oesophagus. They are not 
usually expressed in squamous or gastric mucosa, and are involved only in the 
development of normal intestinal-type mucosa.  
Conjugated bile acids and the inflammatory cytokines Tumour necrosis Factor α (TNF-α) 
and Interleukin 1 β (IL-1β) have been shown to increase CDX1 mRNA expression in vitro in 
colorectal cancer cell lines, but only when the CDX1 promoter is un-methylated or partially 
methylated. Study of bile salt exposure in rat squamous cell lines and in metaplastic cells 
from the rat OGJ have also shown increased CDX2 expression.  
Although the promoter methylation status in squamous epithelium prior to Barrett’s 
oesophagus formation is uncertain, these studies at a molecular level link refluxate with 
increased expression of genes involved development of normal intestinal type mucosa and 
possibly with development of Barrett’s oesophagus. Perhaps this is key to further 
understanding the molecular pathway and explaining the well known epidemiological 
associations20-22. 
1.4.2 Barrett’s dysplasia and carcinoma pathogenesis. 
Once Barrett’s oesophagus is established it remains unclear which changes lead to 
adenocarcinoma, but inflammatory pathways are key. 
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 The healing of oesophagitis with acid suppression and experiments with bile salts causing 
acid disassociation constant (pka) dependent mucosal injury demonstrate the role of acid 
and bile salts in inflammation. More specifically Taurine-conjugated bile salts cause chronic 
mucosal injury when the oesophageal reflux is acidic (pH 4); glycine-conjugated bile salts 
when the pH is 4–6; and un-conjugated bile salts when the pH is neutral or alkaline23. 
Clinical studies demonstrating prolonged episodes of acid reflux and higher levels of 
oesophageal taurine-conjugated and un-conjugated bile salts in patients with Barrett’s 
oesophagus, tie the principles together. Acid and bile as the causes of inflammation in 
Barrett’s seem certain24-28.  
At a molecular level the causes are less certain. Chronic acid and bile salt injury induce 
reactive oxygen species and free radicals, depleting antioxidants and increasing the 
expression of oxidative-stress-related genes29.  Reduced levels of glutathione and vitamin C 
in the metaplastic epithelium indicate that anti-oxidant defences are compromised, and 
high levels of  oxygen free radicals and lipid-peroxidation products confirm this29.  
Primary free radical DNA damage results in genetic change which may include key cell 
regulatory genes, and therefore a molecular beginning for the neoplastic process.  Cells 
with such mutations would usually undergo forced cell-cycle arrest or apoptosis by a P53 
dependent mechanism. However, bile salts and inflammation prevent this through 
proteosome mediated P53 degradation and migration inhibition factor by-pass of P53 
function allowing genetic abnormalities to accumulate8, 30. Multiple other pathways are 
likely to contribute. Inflammatory stimulus of prostaglandin synthesis through the 
arachidonic acid pathway (Figure 3 below) is also important. Inducible cyclo-oxygenase-2 
(COX-2) is found in increasing amounts through dysplasia and carcinoma31 with 
prostaglandin E2, one of the main product types from the COX-2 pathway, increasing cell 
proliferation32. 
  Gastro-intestinal cancers in the UK. 
1-24 
 
 Protein kinase C and P38 mitogen activated protein kinase (MAPK*) pathways are 
proposed as further growth promoting mediators of the increased COX-2 products 33, 34.  
Lastly experiments treating cell lines with pulsed acidified bile show an important role for 
the C-myc oncogene protein, contributing to uncontrolled cellular growth35  
Figure 3 COX II pathways in Barrett’s oesophagus. 
 
 
* Previously known as Extra-cellular regulated kinase (ERK). 
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Together these findings provide evidence for bile and acid reflux driving genetic and 
molecular change, leading to the accumulation of genetically abnormal cells, with a pro-
proliferative drive able to escape the normal cell cycle controls. Cells become dysplastic 
and finally cancerous.  
Clinical observations demonstrate a more complex understanding is needed, with neoplasia 
development despite healing of oesophagitis and also following acid suppression with a 
proton pump inhibitor (PPI).   
Some evidence to explain this follows from prolonged proton pump inhibitor (PPI - acid 
suppressing medication) usage itself. Secondary bacterial colonization of the gullet at 
neutral pH can produce inflammatory de-conjugated bile salts which continue to inflame 
the gullet36, and secondary hyper-gastrinaemia acting at cholecystikinin 2 (CCK2) receptors 
drives cellular proliferation37. Perhaps unsurprisingly even on a PPI up to 80% of patients 
continue to reflux some acid and up to one third bile salts 38-40. 
Human study substantiating the pathological mechanisms in Barrett’s oesophagus is not 
available, with evidence mainly from cell line studies, animal models and case reports30, 41-43. 
This may not accurately reflect human pathophysiology, and therefore molecular 
confirmation for the role of acid and bile reflux in human neoplasia remains unproven. 
1.5 Genetic hallmarks in colon and oesophageal adenocarcinomas. 
Over the last 50 years there have been many studies of genetic change in cancers. 
Observation of genetic, epigenetic, and extra-genetic changes have demonstrated multiple 
pathways to cancer, however an incomplete and confusing picture has emerged. To gather 
and organise this new information a conceptual framework, “hallmarks of cancer”, was 
developed and published in 200044 and updated in 201145.  
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This serves to provide common understanding across cancers whilst allowing work to 
continue searching for further understanding of cancer pathogenesis.  
These “hallmarks of cancer” are: Self-sufficiency in growth signalling; insensitivity to 
growth-inhibitory (antigrowth) signalling; evasion of programmed cell death (apoptosis); 
limitless replicative potential; sustained angiogenesis; and tissue invasion and metastasis44.  
They serves as a useful way to review the main genetic changes found in oesophageal and 
colonic cancer and these are tabulated below.  
Table 1 Hallmarks of colorectal cancers. 
HALLMARKS of 
CANCER (DNA) 
Colorectal cancer 
Genetic change Prevalence Reference 
Self-sufficiency 
in growth 
signalling 
SRC up regulation 90+% Talamonti 1993, Frame 2004. 
C-Myc  up regulation 66% Smith 1993, Sansom 2007. 
K-Ras up regulation 37% Salbe 2000, DeReynies 2008. 
Insensitivity to 
growth-
inhibitory 
(antigrowth) 
signalling 
P53 down regulation 90+% Veloso 2000 
SMAD-4 down regulation  40% Woodford-Richens 2001 
APC down regulation 90+% Sansom 2007 
PTEN down regulation 20% Nassif 2004, Goel 2004. 
Evasion of 
programmed cell 
death 
(apoptosis) 
P53 down regulation  50%  Jansson 2001 
DCC down regulation 50-70%  Forcet 2001 
mir 17-92 up-regulation 100%  Diosdado 2009, He 2005 
TNFRSF6B up regulation  53 - 73% Pitti 1998, Mild 2002. 
SMAD 4 down regulation  40% Woodford-Richens 2001 
Limitless 
replicative 
potential Telomerase up regulation 90%  Engelhardt 1997. 
Sustained 
angiogenesis 
HIF up regulation  44-55%  Cao 2009, Wu 2010. 
VEGF up regulation 37-100% Okuno 2001, Xiong 2002 
MMP 9 up regulation 63-74% Xeng 1999 
TGF-β  up regulation 38% Xiong 2002 
FGF down regulation  -  Mathonnet 2006. 
Tissue invasion 
and metastasis 
E-cadherin down regulation 19 - 33%  Dorudi 1993, Rosivatz 2004 
MMP-9up regulation 20-75% Zeng 1999, Fan 2006. 
TIMP up regulation  42 - 100% Zeng 1995, Murashighe 1996 
nm 23 H(1) down regulation  62% Fan 2006. 
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Table 2 Hallmarks of oesophageal cancers. 
HALLMARKS of 
CANCER (DNA) 
Oesophageal cancer 
Genetic change Prevalence Reference 
Self-sufficiency in 
growth signalling 
SRC up regulation 20% Kumble 1997. 
β-Catenin up regulation  60% Bailey 1998, Seery 1999. 
COX II up regulation  80 - 97% Wilson 1998, Lagorce 2003. 
EGFR / ERBb2 / HER2neu up 
regulation  10 - 70% 
Kim 1997, Al-Kasspooles 1993, 
Hardwick 1997. 
Insensitivity to 
growth-
inhibitory 
(antigrowth) 
signalling 
P53 down regulation  95 -100% Barrett 1999. 
SMAD-4 down regulation 20 - 35% Barrett 1996, Van Dekken 2008. 
P16 down regulation 12 - 100%  Van Dekken 2008, Shi 2008. 
Cyclin D up regulation  30 - 92% Bani-Hani 2000, Murray 2006. 
Cyclin E up regulation  14% Sarbia 1999. 
P27 down regulation  83% Singh 1998 
Evasion of 
programmed cell 
death (apoptosis) 
P53 down regulation 64 - 87%  Younes 1993, Van Dekken 2008. 
P16 down regulation 68 - 75% Wong1997, Klump 1998.  
15 LOX-1 (13-S-HODE) down 
regulation  - Shureiqui 2001 
Fas ligand up regulation 100%  Bennett 1998, Younes 1999. 
Limitless 
replicative 
potential Telomerase up regulation  100% Morales 2001, Shammas 2008. 
Sustained 
angiogenesis 
HIF-1, and 2 up regulation 51 - 60%  Stein 2004, Griffiths 2007. 
VEGF up regulation 64 - 100%  Saad 2005, Von Rahden 2005. 
MMP up regulation  60- 95% Salmela 2001, Grimm 2010. 
Tissue invasion 
and metastasis 
E-cadherin down regulation 100%  Bailey 1998, Washington 1998. 
MMP-1, 7, 12 up regulation 60-95%  Salmella 2001, Grimm 2010. 
TIMP-1, &3 up regulation  53 - 73% Salmella 2001. 
CD-44 up regulation 70 - 75%  Castella 1996, Lagorce 1998. 
β-cathepsin up regulation  73% Hughes 1998. 
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Clearly some changes appear in both cancers but there is temporal heterogeneity in the 
dysplasia carcinoma sequence. From a diagnostic point of view, without knowing the stage 
of disease this makes the diagnostic use of specific genetic changes less attractive. Some of 
the changes can also be found in “normal” patients46. It seems unlikely that a genetic 
signature diagnosing early cancers or dysplasia will emerge, although patterns may suggest 
risk of cancer and subtype. 
1.6 Clinical diagnosis of oesophageal and colonic carcinomas. 
Current clinical diagnosis of gastro-intestinal cancer is based around a clinical history, 
examination, and routine blood tests. The final diagnosis is predominantly made at 
endoscopy with confirmation on histological examination47-50. There are no diagnostic 
blood or stool tests recommended for early or late gastro-intestinal cancers 51. 
The current clinical approach is certainly effective, but early diagnosis of gastro-intestinal 
cancers is unlikely as symptomatic change often occurs late in disease.  Clinical symptoms 
and blood tests are not specific criteria and are often found in the normal population 
without cancer52, 53.  
Clinically this is a well recognised problem. There are  clear costs involved in investigating 
normal patients, but there are also substantial outcome advantages gained from early 
diagnosis54. Fortunately in the UK we have programmes screening for colorectal cancer and 
providing surveillance in Barrett’s oesophagus patients for oesophageal adenocarcinoma48, 
55. 
1.6.1  UK Colorectal cancer screening guidelines. 
Average risk, asymptomatic patients aged 60-70 years of age are offered screening with 
faecal occult blood testing (fOBT) 55.  
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For every 100 participants, the programme is expected to find 20 positive faecal occult 
bloods, detect 2 patients with colorectal cancer and 6 patients with polyps55. 
 While practical and affordable, this system leaves room for improvement 56, 57, with a low 
estimated  point sensitivity  for cancer (40.58%) , and even lower sensitivity for significant 
dysplastic polyps (5.00%)55. Many cancers and pre-cancerous polyps will be missed. Gains in 
sensitivity are made by offering a programme of fOBT testing, but compliance is likely to 
fall over the program timescale. Initial UK compliance rates of  56.8%55 are unlikely to 
improve much, as demonstrated by  American studies, which have a similar patient group 
and which share common health values. Worldwide some programmes only achieve 18% 58-
61 compliance, and put the UK achievement into perspective. It seems unlikely that further 
gains will arise from improved compliance, and opportunities to prevent colon cancer will 
be missed.  
Immuno-histochemical testing for faecal occult blood (iFoBT) will offer some gains62-65 and 
it is likely this will replace fOBT in the near future. The test utilises a specific antibody 
reaction to human globin, labelled with a fluorescing compound. This allows more specific 
and sensitive testing for faecal human blood, and with a numerical fluorescence result 
allows a variable test sensitivity and specificity.  In combination with other risk factors such 
as age weight, sex, and smoking history a tailored risk assessment for the individual could 
be produced. However, the need for faecal sampling remains, and in the longer term 
investment into better screening approaches may be needed to tackle the relatively low 
uptake. 
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Recently a large clinical trial looking at the role of flexible sigmoidoscopy in colorectal 
cancer screening has concluded 66. This demonstrated reduced incidence and mortality 
from colorectal cancer, with improved sensitivity for cancer at 66%, and for polyps of 97%. 
However, the sensitivity of flexible sigmoidoscopy for detecting cancer is limited to the left 
side of the colon, and quality issues regarding completion of the test remain. Compliance 
with the intervention is approximately 1/3 of those invited (although in smaller trials this 
has been as high as 46%)67. This is undergoing national roll out as part of the bowel cancer 
screening programme (BCSP).  
Biomarkers from blood and urine are active areas of research looking at alternative or 
additive strategies to improve the screening programme avoiding invasive testing. This 
would be more acceptable for population screening, and therefore could offer a new gold 
standard.  
Hospital based endoscopic screening in high and moderate risk cancer groups is also part of 
a national approach, advocated by specialist bowel screening guidelines 47. 
1.6.2 UK Barrett’s oesophagus surveillance guidelines. 
Finding Barrett’s oesophagus over 3 cm in length prompts entry into surveillance 
programmes 48. This programme requires upper endoscopy every 2 years. If dysplasia is 
discovered, guidelines recommend more frequent endoscopy (yearly) and the number of 
biopsy samples taken increase.  
This approach to “screening” presents a numbers of difficulties, not least the identification 
of patients with Barrett’s oesophagus within the general population. Current practice only 
identifies Barrett’s incidentally, and estimation of patients not identified for screening 
suggests  20 unidentified : 1 in screening 68.  
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Ongoing study of techniques to diagnose Barrett’s in high risk populations is ongoing, with 
the best so far the cytosponge69.  
Even when in surveillance programmes evidence of improvement over a symptomatic 
diagnostic approach is limited, with many cases discovered at a late stage and often 
inoperable. Outcome data is unimpressive70-77, and worldwide these programmes are areas 
of ongoing discussion78. A randomised trial comparing screening to a symptomatic 
diagnostic approach in Barrett’s oesophagus is currently under way in the UK (Barrett’s 
oesophagus surveillance study - BOSS trial). 
Identification of dysplastic change and early cancer is the main reason for the diagnostic 
difficulties. Visual abnormalities are subtle and in the low prevalence surveillance 
population are easily missed even in expert hands. The current gold standard of systematic 
quadrantic biopsies, designed to overcome this problem, however only samples only 2% of 
the total surface area and the poor diagnostic outcome is therefore perhaps unsurprising. 
Research into improving the detection of abnormal areas in Barrett’s has been ongoing for 
many years. In expert hands, in a high prevalence population, 95% of cases can be 
identified with 2% acetic acid dye spray79. This is an effective and economical technique, 
and if the population prevalence could be enriched this would be a suitable screening 
technique.  
1.7 Conclusions. 
 Oesophageal and colon cancer are important gastro-intestinal cancers, with 23,610 
deaths a year caused by them.  
 Despite a great deal of research over many years, a diagnostic molecular picture 
remains elusive, and their pathogenesis remains incompletely understood. 
 The current gold standard invasive diagnostic tests mainly diagnose advanced 
cancers, even in screening and surveillance programmes.  
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 Better diagnostic testing for early and pre-cancerous neoplasia would almost 
certainly result in better patient outcome.  
 The use of biomarkers to improve current testing for colonic and oesophageal 
neoplasia, or to enrich the incidence in the Barrett’s surveillance population, is a 
desirable area for clinical research. 
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Chapter 2 Circulating markers of gastro-intestinal cancers. 
2.1 Introduction. 
Cancer biomarkers have been sought for many years with prostate specific antigen (PSA) in 
prostatic adenocarcinoma a good clinical example of what can be achieved80.   
The ideal diagnostic marker for cancer is well characterised as a non-invasive test81, 82 which 
is socially highly acceptable, with 100% sensitivity and specificity for all stages including 
pre-cancerous lesions, and correlating with stage and treatment. It must be inexpensive, 
allowing population screening, utilising generally available technology, and be operator 
independent. 
Unfortunately, in colorectal cancer tests there are problems with social acceptability, 
invasiveness, and accuracy 56, 83, and in oesophageal cancer there is no such test. 
Studies of circulating DNA, RNA, proteins and circulating tumour cells have generated many 
potential cancer markers and will be reviewed below, but none have found a clinical 
diagnostic role to date51. 
Routine sampling of blood and urine, using polymerase chain reaction (PCR) assays of 
nucleic acids and enzyme-linked immuno-sorbent assays of proteins (ELISA) are already 
part of accepted clinical practice84-87. Therefore new circulating DNA, ribonucleic acid (RNA) 
and protein markers hold great hope for diagnostic and screening purposes, and research 
in these areas may quickly advance from bench to bedside. 
Circulating cell free DNA (cfDNA) was one of the earliest targets for researchers studying 
cancer88  and is the most established. With established DNA protocols and extensive PCR 
expertise in our laboratory, circulating cfDNA is therefore the focus of this thesis. 
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2.2 Circulating DNA tumour markers – genomics. 
2.2.1 Origins of circulating DNA. 
Circulating DNA in the human blood stream was first described in 1948 by P. Mandel88, and 
since then has been described in many forms .89-91 The quantity and pattern of circulating 
DNA appears to differ in different physiological states including pregnancy92, cancers 90, 91, 
93-102, benign  diseases 103-105,  and after trauma106, 107.  Although the potential of cfDNA to 
act as a diagnostic marker is clear, the origin of the DNA and the mechanisms leading to its 
presence are not clear.  
The most commonly cited theory is that increased and abnormal apoptosis in tissue leads 
to increased circulating DNA. This theory is based around circulating cfDNA fragmentation 
analysis demonstrating a “fragment ladder” phenomenon at multiples of approximately 
180bp, similar to the pattern found in cells apoptosing 108, 109.  
However, there are five main problems with this theory in cancer. Firstly inhibition of 
apoptotic pathways is considered one of the hallmarks of cancer110 so high DNA levels in 
blood don’t seem to correlate with this. Secondly, degradation of apoptotic cells generally 
occurs without DNA spillage and therefore levels of cfDNA should remain largely 
unchanged 111. Thirdly, DNA fragmentation patterns and quantities change as cancer 
progresses, however apoptotic processes do not. Fourthly, in pregnancy circulating 
maternal DNA length is increased, although there is no obvious reason for an increase in 
maternal apoptosis 112, 113.  
Lastly circulating DNA quantities in healthy normal patients and cancer patients can be 
similar 101, 114.  
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A dynamic process combining necrosis and apoptosis seems most likely to explain 
increased circulating DNA in cancer patients. A study of cell lines (following induced cellular 
necrosis, and apoptosis) and further study in patients supports this, demonstrating 
fragments > 10,000 bp as well as an “apoptotic ladder” phenomenon in both108, 115. 
Circulating white blood cells and ‘free’ nucleases are increased in the blood of cancer 
patients 116, 117, and it is possible that these may break larger fragments from necrotic cells 
into multiple smaller pieces. These two observations potentially explain different ‘total 
‘DNA levels as well as different fragmentation patterns in the cancer and normal patients. 
This is an attractive and potentially comprehensive theory. 
However, this is likely to be overly simplistic with findings from other studies seeming to 
paint a more complicated picture. Unexplained observations of homeostatic DNA 
excretion118, 119; cell to cell nucleic acid transfer120-123; cell bound circulating DNA (ccDNA) 95, 
124-126; and immune and genetic modulating nucleic acids127, 128 need to be included to 
complete the full picture.  
Perhaps some processes engendering survival advantage in normal patients are 
advantageous to cancer cells possibly helping evasion of immune regulation, and in the co-
opting of local and distant cells which aid the cancerous process. 
2.2.2 Circulating cell free DNA Studies. 
DNA markers in blood have been researched most frequently reflecting the clinical 
familiarity with blood sampling and the interaction of blood with all cells in the body. Urine 
has not been studied as much but is promising, especially in the study of urological 
cancers129-134. Urine has the advantage of collecting DNA over a period of time, and 
contains mainly smaller fragments, a possible source of enriched tumour DNA135-139.  
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Picking between these two fluids is difficult; the use of urine is advantageous in some 
respects as sampling is non-invasive, however perhaps for screening purposes social 
embarrassment may impact on patient acceptability. Research in both is underway136, 140-143.  
This thesis used blood because of ease of sampling patients at the time of endoscopy and 
surgery. 
Circulating DNA can be isolated from plasma and serum blood products. It is unclear which 
of the two offers the best medium94, 115, 144-149.  Although there is more cfDNA in serum than 
plasma, the source and tumour specificity of the extra cfDNA is uncertain100, 108, 148. It is 
currently felt that contaminating genomic leukocyte DNA may be the source150, 151. Plasma 
has become increasingly accepted as a better, purer source than serum148, 150-154. 
2.2.2.1 Nuclear DNA studies. 
2.2.2.1.1 DNA quantification. 
Across multiple cancer types and multiple genetic sequences total cfDNA quantification for 
diagnostic purposes is encouraging89, 95, 155-158.  
Study results in cancer patients serum show an increase in total DNA quantity, and 
“apoptotic” long fragment (>180 bp) DNA115, 149. Short and long fragment ratios change in 
cancer patients reflecting relatively more “apoptotic” long fragment circulating DNA, and 
providing a more sensitive discriminator between normal and cancer patients.  
Many studies look at prognosis as well as diagnosis, with higher levels of cfDNA generally 
associated with a poorer prognosis96, 159-161. 
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 A single study in the oesophagus studying squamous carcinoma looked quantitatively at 
cyclin D1 oncogene amplification and showed a relative increase in copy number in both 
tissue and plasma, with prognostic significance162. Oesophageal adenocarcinoma has not 
been studied. 
In colorectal cancer a short (115 bp) Alu sequence has been used to accurately quantify 
total circulating serum DNA, with a significant difference (P  0.006) between the cancer 
and control group. A longer (247 bp) Alu sequence, proposed as another measure of 
apoptotic DNA, was also significantly different. However, it was the ratio of long : short 
fragments which performed best at discriminating cancer form normal patients with a 
receiver operating characteristic curve (ROC) of 0.78 149. Alu sequences are a family of 
abundant repetitive DNA elements in the human genome classified as short (<300 bp) 
interspersed elements (Sine). Line or Long interspersed elements are a group of similar 
genetic elements, also found in large numbers throughout the human genome.  A Line 1 79 
bp sequence has also been shown to be significantly elevated in colorectal cancer and a 
Line 1 300 bp sequence in breast cancer serum147, 163 . Line 1 79 bp may prove to be a more 
accurate measure of total DNA with the ability to measure small (<100 bp) DNA fragments 
and reflecting total tumour DNA more accurately.  
PCR analysis of these interspersed element markers is technically simple and economical 
making them an attractive option for diagnostic testing. With the majority of studies above 
looking at advanced cancers using serum, the use of plasma may provide more accurate 
results and may allow testing in early and pre-cancerous disease. In particular study of 
plasma cfDNA in colorectal and oesophageal cancer had not been explored and this forms 
the basis for this research project using ALU and LINE 1 markers. 
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Quantitative study of DNA is not standardised with results affected by purification 
protocols and inflammatory disease, which confound interpretation89, 109, 115, 149, 164-176. The 
careful selection of purification techniques and control groups in the analysis of early and 
pre-cancerous changes is therefore crucial in any future study.  
2.2.2.1.2 DNA hyper-methylation. 
 Diagnostic approaches looking at epigenetic methylation are reported in many cancers and 
pre-cancerous conditions90, 177-179. 
Early papers looking at cancers and dysplastic tissues180 showed the diagnostic possibilities 
studying multiple aberrantly hyper-methylated promoter regions in colonic and 
oesophageal adenocarcinomas181, 182. Difficulties translating the technology into use for 
much smaller quantities of circulating DNA held back advances in this field, however the 
recent and novel use of restriction enzymes 178 and better purification techniques have 
begun to overcome these 183.  This approach requires complex pre-PCR processing of 
samples, and may make interpretation uncertain. 
However, the resulting serum and plasma studies do show different patterns depending on 
cancer type184 and can even discriminate between patients with colon cancer and intestinal 
polyps 185 . 
Transmembrane protein containing epidermal growth factor and follistatin domains (TPEF) 
186, Aristaless-like Homeobox-4 (ALX4) and Septin 9 (S9)177, 179 in particular showed good 
results in colonic neoplasia. S9 has undergone further validation in the only large screening 
study to date, presented in abstract form only187. Disappointingly it had a 37% detection 
rate for stage I early cancers, and only a 50% sensitivity including more advanced cancers. 
The sensitivity for diagnosing adenomas was not reported, and leaves results in 6431/7938 
study participants unexplained 187. This represents the only clinically relevant screening 
study to date. 
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With variation in hyper-methylated genes in normal tissue suggesting that change in the 
methylation pattern is a marker of neoplasia risk rather than diagnostic of cancer 
development188. Further complexity in interpreting results is added by the observations 
that differing methylation patterns are found in cancer patients with the same disease, and 
even differing patterns in the same patients when comparing pre-cancerous changes185.   
Increasing methylation occurs with increasing age and means that control groups must be 
corrected for this, further complicating interpretation.  
With this level of complexity required for interpretation it seems unlikely a diagnostic 
methylation pattern will be found. 
2.2.2.1.3 DNA hypo-methylation. 
Hypomethylation of key oncogene promoter regions may also contribute to oncogenesis, 
allowing increased replication of  cancer promoting proteins189.  A study of circulating 
lymphocyte DNA showed a significant decrease in genomic methylation in patients with 
colorectal adenomas190. Gastric and head and neck cancers have been associated with 
higher risk in individuals with line 1 hypo-methylation191, 192. These techniques also require 
pre-PCR processing and age specific control groups, the same problems with complex 
results are also likely to affect diagnostic testing role. 
2.2.2.1.4 DNA Mutation. 
Genetic mutation is detected in colorectal cancer and adenomas in 23-95% of patients 136, 
137, 193-195, K-Ras, APC and P53 being the most common. Key mutations in cancers can also 
be picked up in plasma, however to date there is no diagnostic combination available and 
the only clinical role is for K-Ras  directing choice of chemotherapy196. 
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Similarly to other techniques, mutation analysis has its problems, with only very low copy 
numbers of circulating mutant genes being present (<1% in adenomas and early colon 
cancers137). The presence of detectable mutations in normal patients who do not develop 
cancer on long term follow up also suggests risk rather than diagnosis and limits its role 46.  
2.2.2.1.5 Loss of heterozygosity, allelic imbalance, and aneuploidy. 
 In patients heterozygous at key regulatory gene sites, demonstrable loss of heterozygosity 
(LOH) in cancer DNA has been shown with microsatellite markers in both tissue and 
circulating DNA138, 184, 197-200.   
A single retrospective cfDNA study in colon cancer identified  59% of cases201 and two 
studies in oesophageal adenocarcinoma identify 81-96% of cases199, 202. In keeping with 
mutation and methylation, testing is likely to reflect increased risk rather than the cancer 
process itself. 
 Single Nucleotide Polymorphisms (SNP) allowing even more accurate mapping of genetic 
changes was hoped to offer a breakthrough with very large micro-array studies conducted 
extensively in tissue. However, whilst the results in tissue have been impressive, there are 
concerns with the feasibility of using this technique on cfDNA 203.  
An initially impressive study in ovarian cancer with SNP markers showed allelic imbalance in 
95% of cancer patients, and no loss of heterozygosity in the normal population. This looked 
like a breakthrough, however surprisingly high DNA levels were also present in the “control”  
population raising the possibility of contaminating genomic DNA. This would significantly 
affect the loss of heterozygosity analysis in the normal population and call the study result 
into question170. With tumour changes not always reflected in blood samples, and other 
doubts over methodology and accuracy 154, 193, 204 microsatellite and SNP results must be 
interpreted with caution.  
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Fluorescence In Situ Hybridization (FISH) techniques looking at larger chromosomal 
amplification and deletion have shown excellent results in tissue. Results in an oesophageal 
study identified HGD and adenocarcinoma with 84% sensitivity and 93% specificity 205. 
Circulating markers have yet to be studied because of technical difficulties with DNA 
quantity, and the requirement for tumour DNA specificity.  
Similarly flow cytometric studies of aneuploidy in Barrett’s oesophagus and oesophageal 
adenocarcinoma tissue have shown excellent results, and represent the single best marker 
of disease206, 207. However, no study to date has identified these changes in blood or urine, 
and it is difficult to see how this would be possible. 
2.2.2.1.6 DNA sequencing. 
Sequencing offers the most accurate assessment of circulating DNA, with information on 
fragment length, copy number, and gene sequence and mutations. Until recently selection 
and gene enrichment were required to analyse particular genomic sequences, but new 
platforms are able to sequence all circulating DNA with excellent results. This technique 
offers the potential to analyse all of the above markers at the same time. 
A new study in breast cancer sequenced all DNA in normal and neoplastic groups, with 
validation in a second set. The results were startling with a ROC of 0.92 for stage I disease, 
and 70% sensitivity with 100% specificity208. Interestingly both Line and Alu DNA elements 
were significant, with Line being more significant. Further work to prove a clinical role is 
required because of the complex statistics and use of whole genomic pre-amplification, 
both of which may produce undetectable biases 209, 210. Repeat analysis by a different 
technique such as PCR, against a clinically relevant non-breast cancer group, could confirm 
its significance. 
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2.2.2.2 Mitochondrial DNA studies. 
Mitochondrial DNA has been studied less frequently and never in oesophageal and 
colorectal cancer. Results are mixed with some studies showing decreased levels 
(MATPase8, ND1)173, 211, and others increased212. Mitochondria lack intrinsic DNA repair 
enzymes and are therefore sensitive to oxidative damage, especially important in 
oesophageal adenocarcinoma pathogenesis.  Quantitative mitochondrial DNA testing may 
therefore complement nuclear DNA quantification.  
Levels are also raised in traumatic conditions and probably inflammatory conditions, which 
are likely to confound previous studies106. The choice of patient and control groups is once 
again important.  
With no previous study of mitochondrial markers in oesophageal and colorectal cancers the 
oxidation sensitive mitochondrial ND1 sequence was chosen to complement study of 
nuclear DNA markers in this thesis211. 
2.3 Circulating RNA tumour markers – transcriptomics. 
The origin of circulating cell free RNA (cfRNA) is uncertain but it is likely to arise from 
similar processes suggested for cfDNA.  
Although damage to DNA is a key step in carcinogenesis not all change leads to cancer. RNA 
levels reflecting cellular and genomic activity was hoped to identify the cancer phenotype 
bridging the diagnostic gap. Unfortunately, normal levels of RNA expression may only differ 
slightly from that seen in cancer cases, and other diseases, making quantification difficult.  
With cfRNA levels in the blood even lower, analysis of circulating RNA is challenging. 
Furthermore optimal purification and processing techniques have not been agreed, and 
interpreting negative studies is therefore difficult. RNA results will require careful 
validation in large populations. 
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2.3.1 RNA marker studies. 
Multiple studies using micro-array gene expression analysis in tissue have identified a wide 
range of differing genes which may be helpful, but unfortunately without a consistent 
picture. A meta-analysis has compared the results across 25 studies and picked out the 
more consistent markers which may be helpful in future studies213. 
In colorectal cancer a micro-array and RT-PCR study identified a 5 gene marker set using 
circulating white blood cell RNA214. Test characteristics in a validating set identified 88% of 
cancers correctly. However, only 67% of the normal group were identified, half of the 
cancer patients had advanced disease, and an indeterminate group still remained after 
analysis. Improvements to the assay will be needed before further clinical evaluation.  
A second micro-array and RT-PCR study used a panel of 7 biomarkers and also tested on 
circulating white blood cell RNA samples. This was found to have a sensitivity of 72%, and 
specificity of 70%215. Most of the subjects (60%) had early cancers, and the control group 
had undergone normal colonoscopy making this one of the best and most clinically relevant 
colon studies to date. Further testing in a larger screening population is needed. 
Telomerase mRNA shows potential, with two small studies in colorectal cancer showing at 
best 82% sensitivity at 100% specificity, although against healthy controls216, 217. Further 
evidence of  potential is shown in a small clinically relevant hepatocellular carcinoma (HCC) 
study including chronic liver disease controls, showing  77% sensitivity and 97% 
specificity218. All three studies require validation.  
Plasma cytokeratin 19 (CK19) a marker for epithelial cells and CEA RNA analysis in cancer 
patients showed a sensitivity of 83%,and specificity of 76%219.  However, other groups have 
not found similar results220 and the study identified advanced cancers from healthy controls, 
suggesting these figures may fall in a clinically relevant validating population.  
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Most recently in abstract form only, an RNA multi-gene signature identified colon cancer 
and adenomas in a validating set analysis using RT-PCR with 82-85% sensitivity221. 
Unfortunately there is no comment on specificity or stage of disease studied but this may 
be useful in future diagnostic work.  
In oesophageal cancer there are 3 studies. Circulating tumour cell survivin mRNA (an anti-
apoptosis gene) has been studied in a small and retrospective study looking at response to 
chemo-radio therapy in oesophageal squamous and adenocarcinoma.  There was only 
significance in non-responders, and RNA was only found in advanced disease 222. More 
promising results in bladder cancer with urine sampling showed a difference between 
normal and bladder cancer patients that increased with grade of tumour. This finding 
requires further validation, but shows some potential for future research134, 223.  
In oesophageal squamous cancer, plasma  carcinoembryonic antigen (CEA) and squamous 
cell carcinoma (SCC) antigen mRNA   (markers of circulating tumour cells) 224, showed a 
prognostic significance when either SCC or CEA was detected. However, these were only 
present in 13% of patients, (8% CEA antigen and 4% SCC) and reflect advanced disease225. 
These are unlikely to represent diagnostic targets.  
2.4 Circulating protein tumour markers- proteomics. 
2.4.1 Origins of circulating proteins. 
The presence of proteins in plasma is normal, and consists mainly of albumin (55%). Other 
classical plasma proteins include coagulation factors, immunoglobulins, peptide hormones, 
cytokines, and paracrine messengers.  
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Abnormal plasma proteins may be derived from cellular death and damage leading to 
release of non-plasma proteins which can be highly specific e.g. troponin I in cases of 
myocardial infarction. Abnormal secretion patterns in tumour cells may also be a source of 
non-plasma proteins, which whilst being much less controversial than the idea of DNA 
secretion 226 , have still not currently been identified. 
2.4.2 Circulating protein studies 
Approximately 289 plasma proteins have been detected, covering concentrations 10 orders 
of magnitude different. This number is expected to increase and does not reflect all the 
post translational modifications and precursor variations of each protein including 
immunoglobulins with 10,000,000 different sequences.  
Whilst the complexity of the plasma proteomics is apparent, the study of circulating 
proteins also offers great possibilities 226.  
Proteins as the functional products of DNA and RNA are involved in all cell growth and 
change. They also offer great promise in bridging the diagnostic gap between DNA coding 
and cancer phenotype. However, like DNA and RNA there are problems to overcome. 
Protein components of the cellular cancer process can be very subtlety different to ‘normal’ 
cellular proteins quantitatively and structurally. These changes can affect function. There 
are no sensitive and specific assays available at present to detect these subtly different 
proteins. 
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Detection of circulating abnormal proteins can be challenging. Their usual position is 
primarily within the intra-cellular compartment, and circulating levels are therefore much 
lower than other normal circulating proteins. Changing levels of acute phase inflammatory 
proteins, clotting proteins and variation with meals and in other disease states further 
confound analysis227.  Advanced techniques are required to obtain relevant proteins at 
suitable concentrations, which may require prior digestion, or depletion and fractioning. 
These approaches are not standardised, and generation of a protein assay can be laborious 
with small changes difficult to account for. Identifying possible candidate proteins has been 
sped up by using high throughput techniques such as matrix-assisted laser desorption 
ionization time of flight (MALDI-TOF), surface enhanced laser desorption ionization time of 
flight (SELDI-TOF), and mass spectroscopy (MS).  
These offer the possibility to screen very complex proteins mixtures such as urine and 
plasma, identifying individual proteins and protein signatures within them228. Statistical 
analysis of such data is challenging and can be misleading229, with differing signatures 
found in the same cancers, and variability between samples not uncommon230-233. Further 
ELISA testing is generally required to validate and test individual markers234, 235. 
2.4.2.1 Protein signature studies 
An impressive study in colorectal cancer patient’s sera identified six peaks using SELDI-TOF, 
with subsequent development of a validating ELISA assay in a second blinded population. 
 Complement C3a-desArg was the best performing marker in both cancers and adenomas 
with approximate sensitivity and specificity of 96%236. However, the final diagnostic results 
reflected a partial training set and classification did not include lesions that were 
indeterminate. Furthermore the study control group only consisted of healthy volunteers.  
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A second study initially employing mass spectrometry identified five proteins for antibody 
development and further testing in serum. Nicotinamide N-methyltransferase and 
proteasome activator complex subunit 3, were the best performing markers but only just 
improved on CEA237. Comparison between CEA and another putative protein marker 
Macrophage migration inhibitory factor(MMIF) 238 using ELISA also showed little 
improvement. 
There are no oesophageal cancer studies. 
2.4.2.2 Circulating Tumour antigen studies 
Multiple circulating tumour antigens have been developed including those in current 
clinical practice, CEA, CA 19-9, and CA-125.  
Originally they were developed by reacting cancer patients sera with mouse B-lymphocytes, 
and then harvesting the antibodies to test against other cancer patients sera.  
Over time further reactive antigens have been identified and sequenced, although no 
tumour antigens have been identified with any clinical diagnostic role. They represent the 
oldest239 and largest group studied (see Table 3). 
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Table 3 Circulating tumour antigens. 
Name Properties and research roles 
CEA CEA can increase with various GI cancers, allowing follow up and assessment of response to 
chemotherapy240. Studies use combination or comparison to show improved clinical utility.241-243 
CA 19-9 CA 19-9 is a glyco-lipid often raised in pancreatic cancer. Unfortunately it is also expressed in a range 
of other cancers, cystic fibrosis and liver disease244, 245. It can be used to follow up patients and assess 
treatment response51. 
 CA 50  (sialylated Lewis (a) antigen) CA 50 is an alternative antigen epitope of CA19-9. It is no better  and it’s behaviour and use reflects 
this245. 
CA 242 (sialylated Lewis (a) antigen) CA 242 is the final antigen in a triplet against sialylated Lewis (a) antigen, neither is better than the 
other, but perhaps in combination they add some extra sensitivity in detection of pancreatic cancer.246 
CA 125  (Carbohydrate antigen 125, 
MUC 16) 
Ca 125 (MUC16) is a protein associated with ovarian cancer but may be raised in pancreatic and 
colorectal cancers, with other benign conditions. It has follow up, and treatment response roles247. 
CA 72-4 (Tumour Associated 
Glycoprotein TAG-72) 
Ca-72-4 is a tumour associated glycoprotein, with limited specificity for gastric cancer248. 
CA 15-3 (MUC 1) Ca15-3 is a glycoprotein with some specificity for breast cancer at an advanced stage249. 
 
CA 27.29 (MUC 1) CA 27.29 is also an epitope of MUC-1. Elevated CA 27.29 levels are primarily associated with 
metastatic breast cancer and may be useful for predicting recurrent breast cancer. CA 27.29 levels are 
not useful for screening or diagnosis of malignant disorders250, 251. 
CA 11-19  The EDP Biotech company reports that this protein in a test (Colomarker) is able to pick 99% of 
patients with colorectal cancer from the normal population. There are no published trials of this 
marker in pubmed. 
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2.4.2.3 Autologous T-cell activating antigen studies 
Autologous T-cell activating class I MHC antigens are a new avenue for investigation with new 
markers isolated after investigation into melanomas, oesophageal cancer, astrocytoma, and Hodgkin 
lymphoma; NY-ESO-1; MAGE;  GAGE; BAGE; tyrosinase; SSX2; TRP-I; CDK4; and ı-catenin. 
Tissue expression studies in colon252 and oesophageal cancers253 look promising, but studies of 
circulating markers are mostly still awaited. 
A study looking at a single patient with circulating antibodies to T cell derived antigen NY-ESO-1 in 
metastatic adenocarcinoma found higher titres associated with progressive disease254.  
In advanced oesophageal cancer serum NY-ESO-Y1antigen identified only 30% of cases but in 
combination with a FAS ligand antibody identified 89% of tumours with 100% specificity255. With 
poor availability of any markers in oesophageal cancer this may warrant further study. 
2.4.2.4 Auto-antibody studies 
Detection of serum antibodies to tumour antigens in a reverse ELISA may provide useful circulating 
serum markers for cancer diagnosis and prognosis256. These markers are of course the opposite of 
protein antigens above, and testing consists of ELISA with bound peptides selectively binding auto-
antibodies from cancer patient’s sera.  Secondary analysis allows identification of the individual 
antigens. 
In colorectal cancer a combination of five auto-antibodies picked by screening peptides produced 
from cancer complementary DNA (cDNA) libraries, show a diagnostic sensitivity of 58%, and 
specificity of 92.4%. Addition of CEA analysis to these further increases the sensitivity to 77.6%, a 
good clinical test. However, the comparator group were healthy volunteers and no validation 
exercise has been performed257.  
Breast and lung cancer studies have shown more promising results258, 259, perhaps demonstrating the 
difficulties in diagnosing colorectal cancer. 
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In a single study of Barrett’s oesophagus, oesophageal squamous and adenocarcinomas, anti-P53 
antibodies were detected in plasma. However, the diagnostic yield at 11% in Barrett’s patients, and 
20% in oesophageal adenocarcinoma was very low and is unlikely to help diagnostically 260. 
2.4.2.5 Miscellaneous protein studies 
2.4.2.5.1 MMP - matrix metalloproteinases 
A model to detect colorectal cancers and significant polyps, using gender, smoking history, pain, and 
age adjusted ELISA MMP9 levels demonstrated a sensitivity of 78%, and specificity of 77% 261. 
However, 45% of patients had advanced disease and the control group included 46 healthy 
volunteers. These proteins catalyse the dissolution of the extracellular matrix, and perhaps identify 
more advanced aggressive disease moving towards an invasion phenotype. They therefore may not 
be the best marker for early disease.  
MMP7 has been studied in colorectal cancer, but there was only a statistically significant change in 
advanced cancers, suggesting it is less suitable for diagnostic work.262 
MMP2 has been studied with CEA but has lower serum sensitivity (11.1% vs 27.8% in Dukes A). 
Similar to CEA it is useful if high in the primary tumour, associated with worse prognosis and higher 
recurrence263-265. Together the two markers were more sensitive, (28-33%) but not significantly 
better than current markers264, 266. 
2.4.2.5.2 TIMP 1 (Tissue inhibitor of metalloproteinases) 
Impressive results with ELISA kits in a large number of patients show promise in early cancer 
diagnosis, with 52% sensitivity at 98% specificity 267 and even higher sensitivity in early cancers (56% 
in Dukes A and B268). A pre-operative study showed correlation with stage and outcomes, suggesting 
a role in post-operative decision making265. However, a lack of positive findings in adenomas, and a 
correlation with age269 may limit its usefulness as a screening tool for colorectal cancer prevention. 
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2.4.2.5.3 Tissue Polypeptide antigen - cytokeratins 8, 18 and 19 
This is an antibody to epithelial cytokeratin fragments 8, 18, and 19. It has been trialled as a 
circulating marker for colorectal cancer but the results have been mixed with positive and negative 
results 270, 271.  
2.4.2.5.4 Specific Tissue Polypeptide antigen – cytokeratin 18 
This is an antibody to epithelial cytokeratin fragment 18. A trial using it as a circulating marker for 
colorectal cancer met with little success271 . Another study in lung cancer also demonstrated a low 
sensitivity (40%) and use as a diagnostic marker is therefore unlikely272. 
2.4.2.5.5 CYFRA 21-1 – cytokeratin 19  
A study in oesophageal squamous and adenocarcinoma showed a low sensitivity and specificity273. 
Further study of cytokeratins in gastrointestinal cancers is unlikely to add to diagnostic testing, at 
least with ELISA. 
2.4.2.5.6 Nuclear matrix protein antigens  
Nuclear matrix protein markers in cancer patients serum and urine have been described since 
1992274, 275, with an FDA approved diagnostic urinary test in bladder cancer276. Colon cancer specific 
proteins 2, 3, and 4 are new nuclear matrix markers initially picked using mass spectrometry analysis 
and re-analysed with an ELISA against normal, adenomatous, and colon cancer patients serum277-279.  
Control groups were healthy volunteers, patients with hyperplastic polyps, and non-advanced 
adenomas. Testing for “significant” polyps and colon cancer patients showed the test appears 
sensitive with excellent Receiver Operator Characteristics (area under curve 0.82-0.90). This will 
require further evaluation in a larger study. 
Nucleosomes which consist of  nuclear matrix proteins and associated DNA are unfortunately less 
sensitive than cfDNA 280, and so further analysis is unlikely to improve diagnostic testing.  
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2.4.2.5.7 VEGF – vascular endothelial growth factor 
Studies looking at serum VEGF levels have shown significant differences between cancer and normal 
patients281, 282, however in a small study comparing this with circulating DNA, it was less useful.283 
This would seem to preclude a diagnostic role for serum VEGF levels, particularly with bigger more 
advanced tumours requiring enhanced vascular supply. 
2.4.2.5.8 CD 44 
CD44 is a transmembrane glycoprotein family with multiple roles, including cell to cell interactions. 
The exact role depends on the particular isoform. It has been suggested as a marker of breast and 
prostate cancer stem cells284, and changes in cd44 have been associated with tumour metastasis285.  
A clinical trial in different intestinal diseases and cancer patients found significant differences from 
normal patients286. However, when 3 antibodies were used to detect early colon cancer only 25-50% 
of patients were identified, and only 63% of patients with non-metastatic gastric cancer were 
identified. It is therefore unlikely to play a major role in diagnostic testing of cancer in the gastro-
intestinal tract. 287. 
2.4.2.5.9 Kallikrein 
Kallikreins are a subgroup of serine proteases which cleave proteins. Within cancer tissue Kallikrein 
hK3 has a very well recognised role as a cancer biomarker, but by an alternative name, PSA.   
Physiologically hK1 releases bradykinin from kininogen, and plasmin from plasminogen. The role in 
enzyme pathways for other members of this family is not known however they play a prognostic role 
in other types of cancer, including colorectal cancer, in both tissue and serum288-292. There have been 
no diagnostic studies to date. 
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2.4.2.5.10  Laminin 
In colorectal cancer a serum ELISA assay for laminin showed a sensitivity of 89% and a specificity of 
88%. Nearly half of the patients had advanced disease, including metastasis and the control group 
were healthy controls. Further studies are needed293. 
2.4.2.5.11 βHCG - beta human chorionic gonadotrophin 
This was trialled as a circulating marker for colorectal cancer with little success271. 
2.5 Circulating tumour cells. 
Circulating tumour cells offer hope acting as diagnostic, prognostic and therapeutic markers. They 
always signify cancer when detected, but are found mainly in late/ advanced disease and in small 
quantities, representing a metastatic phase.  
They may play an important role in therapeutics and individualised chemotherapy regimens 294-296, 
but their use prognostically shows mixed results 219, 297-300. As they generally detect cancer at a late 
stage they are unlikely to play a diagnostic role with late disease generally symptomatic and 
accurately diagnosed within currently available practice 301, 302.  
Alternative techniques using analysis of cytokeratin mRNA in purified blood220, 224, 303 can detect the 
presence of circulating cells at an earlier stage. Unfortunately as RNA and not the cell itself some of 
the advantages are lost and the later stage of disease remains difficult to surmount diagnostically. 
2.6 Circulating DNA markers in colonic and oesophageal adenocarcinoma. 
Worldwide there are 27 papers looking at the diagnostic and prognostic application of cfDNA 
markers in colonic and oesophageal adenocarcinoma.  All are nuclear DNA studies. The papers 
report quantitative DNA fragmentation changes, tumour suppressor gene promoter 
hypermethylation, patient lymphocyte DNA tumour suppressor gene promoter hypermethylation 304, 
oncogene mutations, and loss of heterozygosity at tumour suppressor genes. 
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The main studies in colonic cancer are tabulated in Table 4 and  consist of 22 papers in English, 1 
paper in Japanese (English abstract, Hibi et.al.305), and 1 in abstract form only (Church et.al.187).  
There are 3 papers looking at oesophageal adenocarcinoma, these are tabulated in Table 5. 
Most studies involve patients with advanced cancer (stages III-IV), commonly representing half of 
the study population. These may not represent patients with curable disease.  
There are only 5 studies looking to identify colonic adenomas136, 137, 140, 187, and no studies look to 
identify oesophageal dysplasia. 
 There are only 4 papers with clinically relevant control groups137, 187, 304, 306. Eight papers don’t report 
findings in control groups, and fifteen use ‘healthy volunteers’, which may not represent a good 
control population. There are no studies of oesophageal adenocarcinoma using clinically relevant 
control groups such as patients with risk factors for cancer or other diseases. 
These markers hold great promise for future study, but none are used clinically yet, and most don’t 
identify early disease.
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Table 4  Colorectal circulating DNA papers. 
 
                                                                                                                                                                     * = only tested in positive tissue patients. I-IV = staging grade of cancer, early (I) to advanced(IV). 
Table 5 Oesophageal circulating DNA papers. 
 
Author Year DNA marker Serum / plasma / urine Control group (n=) Cancer / adenoma (n=) Validation
Prognostic / diagnostic / 
therapeutic
Sensitivity Specificity
Hibi 1998 LOH at 8 microsatellite markers serum N/A I-IV cancers (44) N diagnostic 0% XXX
Anker 1997 K-ras mutation plasma healthy volunteer (6) adv cancer (14) N diagnostic 43% XXX
De Kok 1997 K-ras mutation serum N/A adv cancer (14) N diagnostoc 43% XXX
Kopreski 1997 K-ras mutation serum or plasma healthy volunteer (28) adv cancer (31) N diagnostic 39% XXX
Ryan 2003 K-ras mutation serum N/A I-IV cancers (78) N prognostic 41% XXX
Su 2005 K-ras mutation urine N/A cancer/adenoma (20) N diagnostic 83%* XXX
su 2008 K-ras mutation urine N/A cancer/adenoma (20) N diagnostic 95%* XXX
Hibi 1998 P53 and K-ras mutation serum N/A I-IV cancers (44) N diagnostic 23% XXX
Wang 2004 APC, TP53, K-ras mutation serum healthy volunteer I-IV cancers (104) N diagnsotic 35% XXX
Diehl 2005 APC mutation plasma age matched volunteer (10) I-IV cancer (22) (and polyps(11)) N diagnostic 72% *(39%) XXX
Diehl 2008 APC, TP53, PIK3CA mutation plasma N/A I-IV cancers (25) N diagnostic 50% XXX
Frattinin 2008 K-ras mutation, P16 methylation. plasma healthy volunteers (20) I-IV cancers (70) N diagnostic 25% XXX
Lecomte 2003 K-ras mutation, P16 methylation plasma N/A I-IV cancers (58) N prognostic 64% XXX
Ally 2005  oestrogen receptor methylation leukocytes disease free control group (57) cancer (57) N diagnostic non significant non significant
Grutzman 2008 Sept9 methylation plasma healthy volunteer (183) I-IV cancer (126) Y diagnostic 72% 90%
De Vos 2009 Sept9 methylation plasma healthy control (97) I-IV cancer (172) Y diagnostic 56% 95%
Church 2010 Sept9 methylation plasma ave risk group (930) I-IV cancer and polyps (53) Y diagnostic 50% 91%
Tanzer 2010 Sept9 and ALX4 methylation plasma health volunteer (22) cancer/adenoma (54) Y diagnostic 40% 95%
Holdenrieder 2001 Nucleosome DNA quantification serum healthy and benign disease (172) various adv cancer (418) N therapeutic N/A N/A
Thijssen 2002 pico green DNA quantification serum or plasma age matched volunteer (28) adv cancer (26) N prognostic XXX XXX
Umetani 2006 Alu 115 +247 DNA quantification and ratio serum healthy volunteer (51) adv cancer (136) N diagnostic 63% 92%
Pucciarelli 2009 Alu 115 +247 DNA quantification plasma healthy volunteer (55) I-IV cancer (136) N diagnostic 79% 86%
Flamini 2006 G-3-PD DNA quantification plasma healthy volunteer (75) I-IV cancer (75) N diagnostic 81% 73%
Boni 2007 Rnase P DNA quantification plasma healthy volunteer (67) cancer (67) N diagnostic 100% XXX
Author Year DNA marker Serum / plasma / urine Control group (n=) Cancer / adenoma (n=) Validation
Prognostic / diagnostic / 
therapeutic
Sensitivity Specificity
Kawakami 2000 APC methylation plasma healthy control (20) I-IV cancer (52) N prognostic 25% 100%
Eisenberger 2006 LOH at 12 microsattelite markers serum healthy volunteer (10) cancer (32) N diagnostic 81% XXX
Banki 2008 β-actin plasma healthy volunteer (44) recurrent cancer (42) N prognostic 100% XXX
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2.7 Conclusions. 
 The characteristics of ‘ideal’ diagnostic markers for the early detection of cancer 
have been well described, and circulating markers offer many of these features. 
 A number of research studies into circulating DNA, RNA, and proteins have identified 
potential markers which may be useful diagnostically and prognostically. However, 
none have been proven clinically suitable to date.  
 DNA, with well established sensitive analytical techniques offers a pragmatic area 
for further research, with the possibility of rapid, inexpensive translation into clinical 
practice.  
 Alu, Line and mitochondrial DNA quantification in plasma offers the opportunity for 
an economical and sensitive diagnostic assay for both oesophageal and colorectal 
cancers. 
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Experimental Hypothesis and Aims 
Hypothesis 
This thesis examines the hypothesis that plasma from patients with pre-cancerous, early cancer and 
advanced colorectal and oesophago-gastric cancers contains increasing quantities and changing 
fragmentation patterns of cfDNA, and that this may have a diagnostic application as part of simple 
blood test. 
This thesis also examines the hypothesis that plasma cfDNA levels and fragmentation patterns from 
patients with pre-cancerous, and early colorectal and oesophago-gastric cancers return to normal 
after endoscopic resection. 
Aims:  
1. To develop assays to determine the quantities of nuclear and mitochondrial cfDNA.  
2. To develop assays to determine the fragmentation patterns of nuclear and mitochondrial 
cfDNA.  
3. To examine the use of nuclear and mitochondrial cfDNA quantities as a potential diagnostic 
test in pre-cancerous, and early colorectal and oesophago-gastric cancers. 
4. To examine the use of fragmentation patterns in nuclear and mitochondrial cfDNA as a 
potential diagnostic test in pre-cancerous, and early colorectal and oesophago-gastric 
cancers. 
5. To examine the effect of combining cfDNA with carcinoembryonic antigen as a potential 
diagnostic test in pre-cancerous, and early colorectal cancers.  
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Chapter 3 Methods. 
3.1 Introduction. 
Previous studies using serum with Alu and Line 1 markers, purified cfDNA fragments >100bp long 
and showed significant discrimination between healthy volunteers and cancer patients. 
 This research project utilised plasma to quantify cfDNA fragments >20bp with Alu, Line 1, and 
mitochondrial markers.  
Plasma processing however requires further technical choices with no accepted standard for DNA 
sampling, processing time, separation, or measurement 152, 154, 307. The available techniques are 
discussed below with the reasons for the subsequent protocols described. The full laboratory 
protocols are documented at the end of the chapter. 
3.1.1 Plasma processing. 
Studies show changes in DNA levels and fragmentation when plasma and serum are left for greater 
than 2-4 hours before processing. Processing within this period is recommended153, 308. No 
differences in quantity or integrity were seen between samples stored at 4°C or room temperature 
within this period. 
A double centrifuge protocol separating plasma from whole blood has shown improved 
reproducibility. Additional cell separation techniques such as histopaque and filtration are probably 
not helpful153, 309, 310. Our isolation protocol processed samples within 4 h, utilising a triple spin 
technique with histopaque separation. This followed our standardised laboratory protocol, chosen 
to reduce cellular contamination, and pre-dating the above research. 
3.1.2 DNA isolation and purification. 
Common DNA isolation techniques include: binding of DNA to silica membranes followed by alcohol 
washing; phenol and sodium acetate washing and precipitation with cold ethanol or iso-propanol 
followed by spinning down and drying.  
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Both methods re-suspend DNA with addition of an aqueous solution. A variation on the silica 
membrane technique is to use microscopic silica coated magnetic beads e.g. Dynabeads. These are 
mixed with the DNA and body fluid solution outside of a magnetic field and then separated from the 
suspensions by attraction of the beads to a magnetic field. The supernatant fluid minus DNA and 
beads is removed by pipette. The technique uses the same chaotropic salts and ethanol washes, but 
is quicker, much easier to mechanise and can be up-scaled for larger use. It does not use centrifuges 
or filters. 
Most papers in the medical literature use silica membrane spin column techniques 108, 139, 147, 154, 167. 
They offer highly standardized tissue specific procedures, quick and easy use, few toxic or harsh 
chemicals, minimise contaminating inhibitors, and are used in NHS laboratories311-313. DNA isolation 
relies on the formation of hydrogen bonds between the DNA and the silica membranes in the 
presence of high concentrations of chaotropic salts, and relative dehydration. The DNA containing 
solution is spun through silica membrane columns which bind the DNA when the conditions above 
are in place. The chaotropic salts are then removed with an alcohol-based wash and spin. The DNA is 
finally eluted after addition of a low-ionic-strength aqueous solution such as TE (10mM Tris-HCl, 0.1 
mM EDTA) buffer or water with a final spin down into a collecting tube.  
Newer columns have been developed for purifying small DNA fragments (<100 bp) thought to 
contain more tumour DNA. Plasma-XS spin columns (Macherey-Nagel) economically purify 
fragments >20 bp long, and are used in this study. 
3.1.2.1 High Yield Plasma-XS nucleospin modification. 
The spin column manufacturer recommends that up to740 µl of plasma can be loaded onto the spin-
column without compromising quantification. With our low concentration samples, it was desirable 
to process larger volumes of plasma. A preliminary study showed that up to 960 μL of our plasma (2x 
480 μL aliquots with 2 x 720 μL of binding buffer, loaded in 4 x 600 μL aliquots) can be loaded 
without losing DNA (Figure 4). 
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Figure 4 Modified DNA loading results. 
 
 
 
3.1.3 DNA quantification. 
Quantitative study of purified cfDNA has been measured in three main ways: absorbance (Ultra 
Violet (UV) spectrophotometry)314; fluorescent DNA binding dyes (e.g. ethidium bromide, Pico 
green)306; and quantitative PCR reaction101, 149, 315.  
UV spectrophotometry is the easiest and most common technique for measuring DNA generally. 
DNA and most of the common contaminants found in DNA preparations absorb UV light and 
measurements between the 220 nm and 320nm region and are used to determine concentration 
and assess purity. Measurement at 260 nm quantifies DNA; 230 nm guanidium salts and phenol 
(process contaminants); 280 nm tyrosine and tryptophan (used as an indicator of protein 
contamination); and 320 nm turbidity of the sample which is normally subtracted after a background 
reading. These separate absorbance readings allow measurement of the DNA concentration and 
provide information about the contaminant levels. 
0 
0.005 
0.01 
0.015 
0.02 
0.025 
0.03 
0.035 
0.04 
0.045 
Sa
m
p
le
 1
.1
 (
4
8
0
μ
l)
 
Sa
m
p
le
 1
.2
 (
9
6
0
μ
l)
 
Sa
m
p
le
 1
.3
 (
1
4
4
0
μ
l)
 
Sa
m
p
le
 2
.1
 (
4
8
0
μ
l)
 
Sa
m
p
le
 2
.2
 (
9
6
0
μ
l)
 
Sa
m
p
le
 2
.3
 (
1
4
4
0
μ
l)
 
Sa
m
p
le
 3
.1
 (
4
8
0
μ
l)
 
Sa
m
p
le
 3
.2
 (
9
6
0
μ
l)
 
Sa
m
p
le
 3
.3
 (
1
4
4
0
μ
l)
 
Sa
m
p
le
 4
.1
 (
4
8
0
μ
l)
 
Sa
m
p
le
 4
.2
 (
9
6
0
μ
l)
 
Sa
m
p
le
 4
.3
 (
1
4
4
0
μ
l)
 
Sa
m
p
le
 5
.1
 (
4
8
0
μ
l)
 
Sa
m
p
le
 5
.2
 (
9
6
0
μ
l)
 
Sa
m
p
le
 5
.3
 (
1
4
4
0
μ
l)
 
Sa
m
p
le
 6
.1
 (
4
8
0
μ
l)
 
Sa
m
p
le
 6
.2
 (
9
6
0
μ
l)
 
Sa
m
p
le
 6
.3
 (
1
4
4
0
μ
l)
 
Sa
m
p
le
 7
.1
 (
4
8
0
μ
l)
 
Sa
m
p
le
 7
.2
 (
9
6
0
μ
l)
 
Sa
m
p
le
 7
.3
 (
1
4
4
0
μ
l)
 
Sa
m
p
le
 8
.1
 (
4
8
0
μ
l)
 
Sa
m
p
le
 8
.2
 (
9
6
0
μ
l)
 
Sa
m
p
le
 8
.3
 (
1
4
4
0
μ
l)
 
Sa
m
p
le
 9
.1
 (
4
8
0
μ
l)
 
Sa
m
p
le
 9
.2
 (
9
6
0
μ
l)
 
Sa
m
p
le
 9
.3
 (
1
4
4
0
μ
l)
 
Sa
m
p
le
 1
0
.1
 (
4
8
0
μ
l)
 
Sa
m
p
le
 1
0
.2
 (
9
6
0
μ
l)
 
Sa
m
p
le
 1
0
.3
 (
1
4
4
0
μ
l)
 
1 2 3 4 5 6 7 8 9 10 
M
e
an
 q
u
an
ti
ty
 o
f 
D
N
A
 (
n
g/
μ
l)
 
Modified protocol - total DNA yield 
   
3-61 
 
Absorbance value at 260 nm (A260) is used to calculate DNA concentration with an equation derived 
from Beer’s Law: 
Concentration (µg/mL) = (A260 reading – A320 reading) x dilution factor x 50 µg/ml.  
 A260 of 1.0 = 50 µg/mL pure DNA.  
Proteins and guanidium salts do contribute to absorbance at A260, therefore if they are present at 
high levels in low concentration DNA preparations they will lead to an overestimation of the DNA 
concentration312. A good quality DNA sample should have an A260/A280 ratio of 1.7-2.0 and an 
A260/A230 ratio of greater than 1.5.  
The nanodrop spectrophotometer 1000 (Thermoscientific) is accurate (± 10-15%) when samples are 
greater than 10 ng/μL, and is unsuitable for the purified DNA samples we are using at <3 ng/μL. 
There is also no information about relative quantities of specific genes or fragmentation patterns 
offering a potentially more sensitive test. Therefore this method was not chosen for the main study. 
Quantitative fluorescent DNA dyes e.g. ethidium bromide, fluoresce markedly when bound to 
double stranded DNA. Isolated DNA is usually loaded onto an agarose gel and separated according to 
size and charge by exposure to an electric field. The negative charge associated with the DNA 
backbone causes migration towards the anode. The dye is then applied to the gel and the DNA 
concentration is calculated by a fluorometer comparing fluorescent intensity to that of a known 
concentration and molecular weight marker band. This technique can provide information on 
specific genes, fragment size and DNA quantity, however DNA content less than 10 ng is very difficult 
to measure on agarose gels. Therefore this technique is also not suitable for our purposes. 
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Pico Green is a newer double-stranded DNA binding fluorescent dye. It works in solution comparing 
the unknown DNA to a prepared standard curve of appropriate DNA and is more sensitive, able to 
detect pg of DNA. However, 200 bp fragments are required for successful quantitation316; genomic 
and fragment DNA each require their own standard curves; there is no information about relative 
quantities of specific genes; and fragmentation pattern analysis is not possible. This technique is also 
not suitable for our purposes. 
The last and most recent technique uses quantitative real time PCR (qPCR) a development from 
standard PCR. It allows the measurement of the target sequence PCR product as it replicates by the 
generation of a DNA bound fluorescent signal. The fluorescence signal increases with each 
amplification cycle. The PCR cycle number at which the exponentially rising fluorescence first 
increases significantly above the background, is called the threshold cycle (Ct). This provides an 
inverse quantitative relationship to the original DNA concentration of the amplicon. 
Absolute qPCR for DNA quantitation is well established in the forensic science community, as well as 
the medical research community317. Research has shown it to be highly accurate and reproducible 
with blood and plasma, even at low picogram DNA concentrations149, 318. Absolute qPCR also relies 
on a standard curve methodology, but is not reliant on similar fragmentation size.  
With the use of differing size amplicons either side of the “apoptotic fragment” size e.g. 79 bp and 
300 bp, this technique allows highly accurate and reliable quantitative and fragment analysis of both 
nuclear and mitochondrial DNA. This technique was chosen for our analysis and has previously been 
used with Alu, Line and mitochondrial markers. 
Whichever methods are chosen caution must be used when comparing yields. Contaminants, 
accuracy, and reaction efficiency differences may cause variable measurements and results. 
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3.1.4 Absolute qPCR. 
3.1.4.1 Primer selection and optimization. 
A sufficient magnesium (Mg2+) concentration is an essential component required for DNA 
polymerase function, however too much Mg2+ can cause non-specific amplification. Primer 
concentration must also be at a level that allows optimal efficiency of the reaction, but not so high 
that non-specific annealing and primer-primer interactions occur (primer-dimers). It is therefore 
essential to optimise these two factors specifically for each target. 
The primers were tested for optimal conditions initially with 3 master mixes, mix A std 
manufacturers double strength master mix, mix B = + 1 mM MgCl2, and mix C = + 2 mM MgCl2. 
Forward and reverse primers were tested at concentrations of 100 - 400 mM in a grid formation. A 
positive control to confirm PCR reaction, and a 400/400 mM concentration negative control was 
added to rule out primer-dimer artefacts (Table 6.). Preliminary Ct results for Line 1 79 bp are shown 
in Table 7. The concentration of 400 mM forward and reverse primers without additional 
magnesium was chosen for efficiency and ease of preparation. 
Table 6 Optimization experimental layout. 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 
MM A 
15ul 
MM A 
15ul 
MM A 
15ul 
MM B 
15ul 
MM B 
15ul 
MM B 
15ul 
MM C 
15ul 
MM C 
15ul 
MM C 
15ul 
     F1 5ul F1 5ul F1 5ul F1 5ul F1 5ul F1 5ul F1 5ul F1 5ul F1 5ul 
     R1 5ul R2 5ul R4 5ul R1 5ul R2 5ul R4 5ul R1 5ul R2 5ul R4 5ul 
     
            
B 
MM A 
15ul 
MM A 
15ul 
MM A 
15ul 
MM B 
15ul 
MM B 
15ul 
MM B 
15ul 
MM C 
15ul 
MM C 
15ul 
MM C 
15ul 
 
MM B+ve 
13ul 
MM B-ve  
13ul 
  F2 5ul F2 5ul F2 5ul F2 5ul F2 5ul F2 5ul F2 5ul F2 5ul F2 5ul 
 
F2 5ul F4 5ul 
  R1 5ul R2 5ul R4 5ul R1 5ul R2 5ul R4 5ul R1 5ul R2 5ul R4 5ul 
 
R2 5ul R4 5ul 
  
          
2ul DNA 2ul water 
C 
MM A 
15ul 
MM A 
15ul 
MM A 
15ul 
MM B 
15ul 
MM B 
15ul 
MM B 
15ul 
MM C 
15ul 
MM C 
15ul 
MM C 
15ul 
     F4 5ul F4 5ul F4 5ul F4 5ul F4 5ul F4 5ul F4 5ul F4 5ul F4 5ul 
     R1 5ul R2 5ul R4 5ul R1 5ul R2 5ul R4 5ul R1 5ul R2 5ul R4 5ul 
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Table 7 Optimization experimental results for line 1 79bp primer. 
Well Identifier Ct Well Identifier Ct Well Identifier Ct Well Identifier Ct 
A01 MMA 100/100          22.4 A05 MMB 100/100          20.7 A07 MMC 100/100          21.3 
   
A02 MMA 100/200          20.6 A04 MMB 100/200          N/A A08 MMC 100/200          20.8 B11 MMB 200/200   18.6 
A03 MMA 100/400          20.9 A06 MMB 100/400          20.5 A09 MMC 100/400          20.6 
 
+ve control 
 
B01 MMA 200/100          19.4 B04 MMB 200/100          19.4 B07 MMC 200/100          N/A B12 MMB 400/400      N/A 
B02 MMA 200/200          19 B05 MMB 200/200          N/A B08 MMC 200/200          19.6 
 
-ve control 
 
B03 MMA 200/400          18.9 B06 MMB 200/400          18.9 B09 MMC 200/400          19.6 
   
C01 MMA 400/100          19.3 C04 MMB 400/100          19.8 C07 MMC 400/100          20.5 
   
C02 MMA 400/200          18.8 C05 MMB 400/200          19.6 C08 MMC 400/200          19.6 
   
C03 MMA 400/400          18.7 C06 MMB 400/400          19 C09 MMC 400/400          20 
   
 
Melt curves to look for non-specific amplification and evidence of primer-dimers were analysed, e.g. 
Figure 5. 
Figure 5 Melt curve for Line 1 79 bp 400/400 primer amplification. 
 
Standard curves were tested in the optimised PCR conditions to ensure appropriate efficiency, range 
and correlation (R2). R2 Values greater than 0.995 were achieved confirming accuracy of 
experimental standard curve in each case. 
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Figure 6 Line 1 79 bp standard curve.  
R
2
 = 0.998. 
.  
3.1.4.2 Amplicons and cycling conditions. 
The 5 previously described amplicons are detailed in Table 8. 
 Table 8 PCR amplicons. 
 
The plate setup for all amplicons and experiments is shown in Table 9. 
  
Name Sequence 5’-3’   (forward and reverse primer) Product length [Primer]nM Source
5'-CCTGAGGTCAGGAGTTCGAG-3' 200
5'-CCCGAGTAGCTGGGATTACA-3' 200
5'-GTGGCTCACGCCTGTAATC-3' 200
5'-CAGGCTGGAGTGCAGTGG-3' 200
5’-AGGGACATGGATGAAATTGG-3' 400
5’-TGAGAATATGCGGTGTTTGG-3' 400
5'-ACACCTATTCCAAAATTGACCAC-3' 400
5'-TTCCCTCTACACACTGCTTTGA-3' 400
5'-CACCCAAGAACAGGGTTTGT-3' 400
5'-TGGCCATGGGATTGTTGTTAA-3' 400
Lin, C. S.Interact Cardiovasc Thorac Surg, 2008
Diehl, F. Nat Med 2008
297bp Sunami, E Ann N Y Acad Sci 2008
79bp
108bp
Umetani, N. Clin Chem 2006
247 Umetani, N. Clin Chem 2006
115Alu 115
Alu 247
Line 1 79bp
Line 1 300bp
Mitochondrial ND1
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Table 9 Plate layout for all experiments. 
  1 2 3 4 5 6 7 8 9 10 11 12 
A NTC NTC NTC STD 1 STD 1 STD 1 STD 2 STD 2 STD 2 STD 3 STD 3 STD 3 
B STD 4 STD 4 STD 4 STD 5 STD 5 STD 5 
SAMPLE 
1 
SAMPLE 
1 
SAMPLE 
1 
SAMPLE 
2 
SAMPLE 
2 
SAMPLE 
2 
C 
SAMPLE 
3 
SAMPLE 
3 
SAMPLE 
3 
SAMPLE 
4 
SAMPLE 
4 
SAMPLE 
4 
SAMPLE 
5 
SAMPLE 
5 
SAMPLE 
5 
SAMPLE 
6 
SAMPLE 
6 
SAMPLE 
6 
D 
SAMPLE 
7 
SAMPLE 
7 
SAMPLE 
7 
SAMPLE 
8 
SAMPLE 
8 
SAMPLE 
8 
SAMPLE 
9 
SAMPLE 
9 
SAMPLE 
9 
SAMPLE 
10 
SAMPLE 
10 
SAMPLE 
10 
E 
SAMPLE 
11 
SAMPLE 
11 
SAMPLE 
11 
SAMPLE 
12 
SAMPLE 
12 
SAMPLE 
12 
SAMPLE 
13 
SAMPLE 
13 
SAMPLE 
13 
SAMPLE 
14 
SAMPLE 
14 
SAMPLE 
14 
F 
SAMPLE 
15 
SAMPLE 
15 
SAMPLE 
15 
SAMPLE 
16 
SAMPLE 
16 
SAMPLE 
16 
SAMPLE 
17 
SAMPLE 
17 
SAMPLE 
17 
SAMPLE 
18 
SAMPLE 
18 
SAMPLE 
18 
G 
SAMPLE 
19 
SAMPLE 
19 
SAMPLE 
19 
SAMPLE 
20 
SAMPLE 
20 
SAMPLE 
20 
SAMPLE 
21 
SAMPLE 
21 
SAMPLE 
21 
SAMPLE 
22 
SAMPLE 
22 
SAMPLE 
22 
H 
SAMPLE 
23 
SAMPLE 
23 
SAMPLE 
23 
SAMPLE 
24 
SAMPLE 
24 
SAMPLE 
24 
SAMPLE 
25 
SAMPLE 
25 
SAMPLE 
25 
SAMPLE 
26 
SAMPLE 
26 
SAMPLE 
26 
 
After experimental optimization of primer concentrations, magnesium concentration and thermal 
cycling conditions, qRT-PCR was carried out as described in Table 10.  
Table 10 PCR cycling conditions for each amplicon. 
 
Name PCR conditions
Alu 115
Alu 247
Line 1 79bp
Line 1 300bp
Mitochondrial ND1
50⁰C 2 mins, 95⁰C 10mins (30 cycles of: 95⁰C 15s, 51⁰C 30s, 57⁰C 45s).
50⁰C 2 mins, 95⁰C 10mins, (30 cycles of: 95⁰C 15s, 60⁰C 1min).
94⁰C 2 min, (2 cycles of 94⁰C 20s, 67⁰C 30s, 70⁰C 45s), (2 cycles of: 94⁰C 20s, 64⁰C 30s, 70⁰C 45s),                                                                                
(2 cycles of: 94⁰C 20s, 61⁰C 30s, 70⁰C 45s), (30 cycles of: 95⁰C 15s, 59⁰C 30s, 60⁰C 45s). 
50⁰C 2mins 95⁰C 10mins, (30 cycles 95⁰C 15s, 57⁰C 1min).
94⁰C 2 mins, (3 cycles of : 94⁰C 20s, 68⁰C 30s, 72⁰C 30s), (3 cycles of: 94⁰C 20s, 67⁰C 30s, 72⁰C 30s),                                                                   
(3 cycles of : 94⁰C 20s, 66⁰C 30s, 72⁰C 30s), (30 cycles of: 94⁰C 20s, 64⁰C 30s, 72⁰C 30s).
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Each run used either 10 minutes at 95°C (to activate the DNA Taq polymerase), or 2 minutes at 94°C 
and 6-9 cycles of a modified touchdown PCR, before 30 amplification cycles. Each PCR cycle 
comprised denaturing, annealing, and extension. Fluorescence measurements were automatically 
collected at the end of each annealing phase, with baseline measurements collected during cycles 3-
15. At the end of each run a final melt curve cycle was performed to exclude the presence of primer-
dimer artefacts. 
The line 1 79 bp and Alu 115 bp fragments have both been used to quantify circulating DNA levels 
before137, 149. With the Plasma XS nucleospin collecting DNA fragments > 20bp, the Line 1 79 bp 
fragment is referred to as “Total DNA” reflecting the additional <100 bp fragments being collected 
and measured with this technique for the first time. Alu 115 is used as a comparator and as part of 
the Alu 115/247 bp fragment short : long ratio comparison.  
3.1.4.3 DNA quantity calculation. 
The qPCR analyser used for all experiments was the AB7500 (Applied Biosystems inc. California). 
Manufacturer default analysis settings were retained. The Ct value and standard curves were 
calculated automatically on the 7500 software.  
To maximise comparative results across all samples, mean values for standard curve intercept and 
slope were calculated from the nine experimental runs (Table 11).  
Table 11 Mean standard curve values for each primer. 
Line 1 79 Line 1 300 Alu 115 Alu 247 Mito 
Slope CT slope CT slope CT slope CT slope CT 
-3.40 14.77 -3.57 15.27 -3.49 16.78 -4.56 11.34 -3.50 18.92 
0.16 0.53 0.09 0.63 0.12 1.08 0.19 0.62 0.15 1.00 
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These were then used to manually calculate quantities for each individual sample against a single 
standard curve for each amplicon following the AB7500 manufacturer calculation below. The 
standard linear regression equation Y = mX +c was used.  
 Ct = m [log (Qty)] + c  
The slope of the line is m, X is log (Qty), c is the y intercept, and Y is the Ct value.  
Rearranging the equation to solve for DNA quantity: 
Qty = 10 
      
 
 
Standard deviation for each triplicate sample quantity was calculated according to: 
SD =  
X = sample value,  x~  = the sample mean, and n = number of samples.  
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3.1.4.4 DNA dilution correction factor. 
Previously purified high concentration healthy volunteer lymphocyte DNA was measured in triplicate 
using a nanodrop 1000 spectrophotometer following the manufacturer protocol. The mean value 
was 140.79 ng/μL. This sample was diluted 1:29 and used to make a 4.69 ng/μL standard curve 
solution.  This was aliquoted into 10µl samples and stored at -20°C just prior to starting the 
experiments.  
For the experimental standard curves this solution was further diluted 3:85, and then 1:3, and then 
lastly 1:4. The calculated value of 0.1998 ng when compared to the standard curve value used (0.25) 
requires application of a 0.79996 correction factor to the DNA quantity calculated by the AB7500 
data. 
A final dilution factor was calculated incorporating the above standard curve correction. This allows 
conversion of the dilute DNA quantity calculated by the AB7500 into an accurate DNA concentration 
for each mL of whole plasma. 
This factor = 2.083 (correction to millilitres of whole plasma) *40 (1:40 dilution) * 23 (DNA 
purification dilution) * 0.79666 (STD curve quantity correction) = 1533.01.  
 
3.1.4.5 PCR assay co-efficient of variation results. 
Coefficient of variation % is a measure of assay accuracy, and gives a measure of reliability for the 
results. 
It was calculated for each sample triplicate by:  
                
                  
       
The mean of the samples coefficient of variation is also known as the plate inter-assay coefficient of 
variation.  
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To calculate the intra-assay coefficient of variation identical mid-point standard curve triplicate CT 
values across all plates were used to calculate DNA quantities as above. These values were then used 
in the coefficient of variation equation to calculate the intra-assay coefficient of variation (Table 12). 
Table 12 Intra-assay coefficient of variation experimental results. 
 
Line 1 79 Line 1300 Alu 115 Alu247 Mito 
inter-assay 5.59% 12.80% 13.76% 7.98% 14.83% 
Range 0.26-26.05% 0.86-29.34% 0.76-76.33% 0.38-17.59% 0.01-38.48% 
intra-assay 8.60% 9.19% 11.97% 6.23% 10.98% 
 
3.1.5 CEA analysis. 
CEA as the only circulating marker with any diagnostic role in gastrointestinal cancers makes an 
interesting diagnostic comparator51. Testing for CEA in the colorectal neoplasia populations was 
therefore undertaken. 
CEA analysis was performed using a Beckman Coulter Unicel DXL 800 machine (CEA2 assay) with a 
CEA2 kit (CEA Access, Beckman Coulter ref 33200).  This utilised an ELISA assay with Lumi-Phos 530 
(Lumigen PPD (4-methoxy-4-(3-phosphatephenyl)spiro[1,2-dioxetane-3,2’-adamantane], disodium 
salt) as the fluorescent marker, and alkaline phosphatase as the linked enzyme.  
The assay contains two mouse anti-bodies (MAb) with differing epitopes to the CEA protein, one 
linked to a magnetic bead, and the other to alkaline phosphatase. The plasma (35 μL) is aspirated 
from the sample placed in the machine, and incubated together with the MAb before washing and 
separating with a magnetic field. Lumi-Phos 530 substrate is added to the separated magnetic beads 
solution, and a fluorescent reading at 530 nm taken. A stored multipoint callibration curve (0, 1, 10, 
100, 500 and 1000 ng/mL CEA, re-calibrated every 28 days), and daily quality control testing, allow 
accurate “random access” quantification of the CEA level from 0.1 – 1000 ng/mL with 95% 
confidence. 
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3.1.6 Patient choice, pathological grading and disease staging. 
Normal patients had undergone normal upper and/or lower endoscopy without biopsies that were 
otherwise well. This represented a population with symptomatic gastro-intestinal disease that were 
otherwise well.  
Barrett’s oesophagus surveillance patients were included in the group when controlling the 
oesophageal neoplasia study.  
Patients with biopsy proven colorectal or oesophageal neoplasia undergoing endoscopic or surgical 
resection had plasma samples taken pre-procedure. Oesophageal cases planned for neo-adjuvant or 
palliative chemotherapy had plasma samples taken prior to commencing treatment. 
Paired samples were taken from previously consented patients post-resection, when the neoplasia 
was thought to have been resected back to normal. The average follow up period prior to sampling 
was 330 days in colon cases (range 85-753 days) and in oesophageal cases 276 days (range 81-480 
days. All paired samples were endoscopically or biopsy proven to be normal or incompletely 
resected. 
Radiological computed tomography staging was performed by three experienced gastro-intestinal 
radiologists supplemented with endoscopic, laparoscopic and positron emission tomography (PET) 
scanning results. It was the multi-disciplinary team accepted staging. Pathological staging and 
grading was performed by three experienced gastro-intestinal pathologists, who reported in tandem 
for endoscopically resected specimens. The pathological report of the resected specimen was used 
as the definitive stage and grade. The staging system used for all cases was the Tumour Node 
Metastasis (TNM) system. 
3.1.7 Statistical analysis. 
SPSS version 19.0 was used for all statistical analysis. 
Mean and median values were calculated for all variables. 
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The population values were analysed for normality of distribution graphically and with a Shapiro-
Wilk test, and this was not found. Therefore statistical tests for non-parametric data were used. 
To test the statistical significance of the un-paired normal and neoplasia populations the Mann-
Whitney U test was used.  
Using multiple markers increases the probability of statistically significant findings occurring by 
chance. To correct for this a Bonferroni correction factor of 10 was applied raising the significant cut-
off to P= 0.005. 
To evaluate the possibility of diagnostic testing with these markers logistic regression was 
undertaken with receiver operating curves drawn to demonstrate the tests diagnostic possibilities. 
 Logistic regression predicts a dichotomous categorical variable from a set of predictor variables.  It 
does not require a normally distributed data set. The predicted dependent variable is a function of 
the probability that a particular subject will be in one of the categories, in this thesis that the patient 
has neoplasia.  Logistic regression calculates the probability that a specific point is a true member of 
a population by regression of the data to a best fit linear relationship. Multiple markers can be 
analysed and used to improve the model. This analysis uses the default SPSS logistic regression cut-
off, predicting at a probability of ≥ 0.5.  
Receiver operating curves (ROC) curves are used to scrutinise diagnostic probability. They plot the 
false positive rate on the X axis and 1 - the false negative rate on the Y axis, and show the trade-off 
between the two. Effectively this plots sensitivity against specificity at every single cut off.  The area 
under the curve measures the discrimination, or the ability of the test to correctly classify those with 
and without the disease. ROC values 0.90 - 1.0 represent an excellent test, 0.80 - 0.90 a good test, 
0.70 - 0.80 a fair test, 0.60 - 0.70 a poor test, and 0.50 - 0.60 a failed test. 
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3.2 Experimental protocols. 
All methods were carried out in accordance with the control of substances hazardous to health 
(COSHH) regulations, following good laboratory practice. All blood and DNA processing followed 
universal precautions, and were carried out in cleaned class II biological safety cabinets. 
All patients were consented for the study following ethical committee approved protocols and 
national guidelines. Patient information leaflets were supplied. 
3.2.1 Venepuncture. 
Venous blood was taken from a peripheral vein after application of a tourniquet using a 20 millilitre 
(mL) BD Plastipak syringe and a 21 gauge BD needle. Blood was subsequently inserted into a 4.5 mL 
EDTA BD vacutainer. Blood was stored at room temperature for 2-3 hours maximally prior to 
processing. 
3.2.2 Cell and plasma separation. 
A 5 mL aliquot of blood was added to 5 mL of Hanks balanced salt solution (GIBCO 14175,  –MgCl2, -
CaCl2. [Potassium Chloride (KCl 5.33mM), Potassium Phosphate monobasic (KH2PO4 0.441mM), 
Sodium Bicarbonate (NaHCO3 4.17mM), Sodium Chloride (NaCl 137.93mM, Sodium Phosphate 
dibasic (Na2HPO4 anhydrous 0.338mM), D-Glucose (Dextrose) 5.56mM]) 
 in a 30mL polypropylene universal container and inverted 3 times to mix. The mixture was layered 
carefully over 10 mL of histopaque 1077 (Sigma Aldrich 10771) in a new 30 mL polypropylene 
universal container using a sterile 3 mL polypropylene Pasteur pipette  before centrifuging at 600g 
for 30 minutes (1830rpm – Harrier 15/80 MSE centrifuge MSB080.CX 1.5).  
   
3-74 
 
After centrifuging the blood had been separated into 4 layers: half strength plasma (“plasma”) top 
layer; white cells (“buffy coat”) layer; Histopaque 1077 layer; and bottom red cell layer. The top 
“plasma” layer was carefully removed from the underlying “buffy” coat layer with a new sterile 3 mL 
polypropylene Pasteur pipette, watching for any disturbance to the “buffy” coat layer.  The “plasma” 
was re-centrifuged at 400g (Harrier 15/80 MSE centrifuge MSB080.CX 1.5) for 7 minutes, before 
removal of the top part of the “plasma” using a new sterile 3mL polypropylene Pasteur pipette 
without disturbing the bottom pellet. 
 The “plasma” was stored in a 2 mL nuclease-free polypropylene container at -80°C (Sanyo Ultralow 
VIP series -86), before batch processing at the end of the collection period. 
3.2.3 Nucleospin DNA purification. 
Prior to processing  “plasma” was re-centrifuged at 11,050g (Eppendorf microfuge) for 3 minutes in a 
final manufacturer recommended step to remove all contaminating cellular debris.  
Two aliquots of 480 μL of “plasma” were mixed (inverting 3 times, and briefly vortexed for 3 s with 
720 μL of binding buffer in two 1.7 mL nuclease-free polypropylene micro-centrifuge tubes, and 
spun down briefly.   600 µl of the mixture was aliquoted onto a nucleospin column before spinning 
at 2000g for 30 s, and 5 s at 11,000g (Eppendorf microfuge). The flow through was discarded. The 
spin column was re-loaded until all 2400 μL was processed. 
The spin column was put into a new collection tube and 500 μL of washing buffer was added, prior 
to spinning at 11,050g for 30 s. The spin column was put into another new collecting tube and 250 
μL of washing buffer was added, prior to spinning at 11,050g for 3 minutes. Finally the spin column 
was put into a 1.7 mL nuclease-free micro-centrifuge tube, and 30 μL of elution buffer added to the 
spin column, prior to spinning at 11,050g for 30 s. 
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Figure 7 Plasma XS spin protocol. 
             
1. Processed Plasma    2. Repeated plasma spins     3. Elution and wash spins   4.PurifedDNA 
Excess ethanol was driven off from the eluted purified DNA sample by heating at 90°C for 8 minutes 
in a class II cabinet, without laminar airflow. 
DNA was stored at -20°C (Liebherr Pro line freezer), in the micro-centrifuge tubes, defrosting only 
once for processing. A 1 in 40 dilution of the DNA samples was used to maximise residual DNA 
available for further experimentation. 
3.2.4 qPCR. 
All pipette tips and plastic-ware was certified DNase- and RNase-free by the manufacturer. All 
solutions were carefully mixed by vortexing or flicking before pipetting.  
In the clean “reagent only” laboratory and class II biological hood, a 10 μM solution of forward and 
reverse primers was made for each amplicon (100 μM stock solution).  The working solutions were 
stored at 4o for up to 2 weeks at which point they were discarded and fresh working primers were 
made. 
Five master mixes were made containing the following: AB X 2 SYBR Green Master mix™(Applied 
Biosystems; S4438- Sigma, UK),  12.5 μL per well; forward and reverse primers (1μL per well of 10 
μM primer for reactions using 400 nM concentrations, and 0.5 μL per well for 200 nM 
concentrations); and DNase-free water to a total volume of 20 μL per well. The master mixes were 
pipetted into each 96 well plate, checked and sealed.  
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In a separate “template only” laboratory and class II biological hood, 5 μL of 1:40 diluted template 
was added to each reaction well, making a total of 25 μL in each well .  
Control wells were incorporated into the plate design; instead of template, these contained 5 μL 
water and 20 μL of master mix only (NTC - no template controls). 
A 5 point 1:4 dilution standard curve was constructed using a standardised, batched and previously 
prepared aliquot of genomic DNA, with known concentration. This was pipetted in triplicate 
sequentially across the plate. 
All five amplicon plates were made up at the same time using the same genomic DNA sample for 
each standard curve. The plates were stored at 4°C prior to sequential analysis on the ABI 7500 
machine. 
Continual melt curve fluorescence analysis was carried out by cooling to 60°C, and raising the 
temperature to 95°C with a 1% ramp rate. 
3.2.5 CEA analysis. 
Plasma samples were thawed and mixed thoroughly before being placed in a 35 μL Coulter 
autosampler and aspirated. Daily laboratory quality controls checks were confirmed and results 
printed off. 
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Chapter 4 Colon results. 
4.1 Demographics. 
The study population comprised 85 patients, including 35 patients without endoscopic abnormality, 
a group of 26 patients with benign colorectal adenomas, and 24 patients with colorectal carcinomas.  
The reference ‘normal’ group of 35 patients, included 15 men, and was chosen as representing a 
typical population attending for endoscopic investigation but with no detectable abnormality (Table 
13). The mean age of this group was 54.1 years (range 24 - 80 years).  Significant intercurrent 
diagnoses in this group included: osteoarthritis; ischaemic heart disease; pernicious anaemia; and 
peptic ulcer. 
Table 13 Normal population indication for endoscopy. 
Endoscopy indication 
Patient 
numbers 
Dysphagia 5 
Dyspepsia 10 
Ulcer follow up 1 
Haematemesis 2 
Abdominal pain 8 
Change in bowel habit 7 
Family history of cancer 1 
Anaemia 5 
Polyp follow up 1 
Melaena 1 
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4.2 Patient groups. 
The benign colorectal polyp group of 26 patients, included 14 men, and had a mean age of 70.2 
years, (range 56 - 85 years).  
Twenty-nine polyps were removed from these patients, mean size 54.3 mm (range 5 - 200 mm). 
Eighteen of these polyps showed low grade dysplasia (LGD), and had a mean size of 56.1 mm (range 
5 - 200 mm), while 11 polyps showed high grade dysplasia (HGD) mean size 52.5mm (range 28 - 100 
mm). Significant residual polyp remained in 3 patients, and a further blood sample taken from these 
patients is included in the analysis. 
 
The group of cancer patients included 19 men and had a mean age of 71.5 years, (range 49 - 87 
years).  There were four patients with polyp cancers, mean size 41.7 mm (range 25 - 40 mm), but the 
majority had biopsy proven colorectal carcinomas, pathological TNM T staging (pT) : pT0 x 5 (4 
polyps, 1 post radiotherapy); pT2 x 4; pT3 x 14; pT4 x 1. 
In total, both polyp and cancer populations include 50 patients, and 53 plasma samples, with a mean 
age of 71.1 years, (49 - 87 years).  
4.3 Mean and median marker values. 
Table 14 Mean values for all markers. 
Mean 
values 
Age 
years 
CEA 
ng/ml 
plasma 
Total 
DNA ng 
/ml 
plasma 
Mito 
ng/ml 
plasma 
Alu 115 
ng/ml 
plasma 
 Line 300  
ng/ ml 
plasma 
Alu 247 
ng/ml 
plasma 79/300 115/247 
normal 
54.1 0.5 8.6 0.9 24.6 1.6 2.8 6.4 8.3 
Polyps 
71.7 0.7 16.1 2.9 74.4 4.4 5.5 6.4 18.0 
Cancer 
71.4 1.1 29.7 3.8 122.1 4.5 8.7 7.0 14.3 
LGD polyps 
73.4 0.46 15.8 3.5 78.3 5.0 5.4 7.11 20.1 
HGD polyps 
69.1 0.94 16.5 1.91 68.4 3.4 5.5 5.27 14.1 
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Table 15 Median values for all markers. 
Median values 
Age 
years 
CEA 
ng/ml 
plamsa 
Total 
DNA ng 
/ml 
plasma 
Mito 
ng/ml 
plasma 
Alu 115 
ng/ml 
plasma 
 Line 300  
ng/ ml 
plasma 
Alu 247 
ng/ml 
plasma 79/300 115/247 
Normal group 
55.0 0.4 7.2 0.7 24.1 1.6 2.7 5.0 8.4 
Polyps group 
71.0 0.6 12.5 1.4 62.4 3.2 4.9 4.3 16.0 
Cancer group 
72.5 0.5 14.9 1.6 73.1 2.2 4.8 6.1 11.7 
LGD polyps 
73 0.6 12.7 1.5 64.3 3.5 4.8 4.7 18.0 
HGD polyps 
69 1.1 11.9 1.2 34.8 3.1 4.9 4.2 11.0 
 
Each marker was analysed between normal, polyp and cancer populations (Tables 14 and 15).  There 
was an increase in the mean values of all markers with increasing pathological grade, though not all 
these differences were statistically significant from the control population (Table 16).   
Looking at the polyp group separately these patterns were not mirrored in the transition from LGD 
to HGD, and statistically there were no significant differences (Table 16). There was a single patient 
with a LGD polyp represented an extreme outlier, with a total DNA level of 206 ng/ml.  This patient 
was removed from the mean and median data, but is included in all other analyses. 
4.4 Statistical significance - Mann Whitney U-tests. 
Applying a 10 fold Bonferroni correction, the significant P value = 0.005. 
Table 16 Statistical significance testing. 
Mann Whitney-U test P values 
CEA 
ng/ml 
plamsa 
Total DNA 
ng /ml 
plasma 
Mito 
ng/ml 
plasma 
Alu 115 
ng/ml 
plasma 
 Line 300  
ng/ ml 
plasma 
Alu 247 
ng/ml 
plasma 79/300 115/247 
Polyps vs. normal groups 0.288 <0.001 0.001 <0.001 <0.001 0.003 0.189 0.002 
Cancer vs. normal groups 0.425 0.002 0.002 <0.001 0.015 0.001 0.087 0.001 
Polyps and cancer vs. normal 0.267 <0.001 <0.001 <0.001 <0.001 <0.001 0.908 <0.001 
LGD vs. HGD polyps 0.906 0.269 0.557 0.796 0.981 0.655 0.438 0.906 
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As compared with normal controls, patients with benign polyps had significantly raised levels of total 
DNA (p<0.001), mitochondrial DNA (p=0.001), Alu 115bp (P<0.001), Line 1 300bp (P<0.001) Alu 
247bp fragment (p=0.003, and Alu 115/247 ratio (P=0.002) Table 16.  Further investigating the polyp 
populations there were no significant differences comparing LGD polyps to HGD polyps. 
As compared with normal controls, patients with colon cancer had significantly raised levels of total 
DNA (P=0.002), Mitochondrial DNA (p=0.002), Alu 115bp (P<0.001), Alu 247bp (p=0.001), and the 
Alu 115/247 ratio (P=0.001) Table 16. 
Comparison of normal with all neoplasia patients showed that all markers except the Line 1 79/300 
ratio were highly significantly different between the populations (P<0.001).   
4.5 Logistic regression and ROC curve values. 
Table 17 ROC curve characteristics. 
ROC values 
CEA 
ng/ml 
plamsa 
Total DNA 
ng /ml 
plasma 
Mito 
ng/ml 
plasma 
Alu 115 
ng/ml 
plasma 
 Line 300  
ng/ ml 
plasma 
Alu 247 
ng/ml 
plasma 79/300 115/247 
polyps vs normal 0.578 0.767 0.742 0.856 0.756 0.719 0.596 0.732 
cancer vs normal 0.562 0.738 0.743 0.838 0.687 0.764 0.632 0.760 
polys and cancer 0.571 0.754 0.742 0.848 0.725 0.74 0.507 0.745 
 
The best single marker in the polyp population was the Alu 115 (ROC=0.856), with the combination 
DNA marker showing an excellent diagnostic ability (ROC = 0.921) Table 17. 
The best single marker in the colon cancer population was the Alu 115 (ROC=0.838), with the 
combination DNA marker showing a very good diagnostic ability for distinguishing cancer from 
normal in this series (ROC = 0.854). 
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The best single marker for diagnosis of all neoplasia in this population was Alu 115bp (ROC = 0.848), 
with the combination DNA marker showing a very good diagnostic ability (ROC=0.888). This had a 
sensitivity of 81.1%, specificity of 75.8%, positive predicitve value of (PPV) of 84.3%, and negative 
predictive value (NPV) of 71.4% (Figure 8). 
CEA is shown once again to be a poor diagnostic marker for colonic neoplasia, with no significant 
difference between the populations. The ROC values indicating failure to discriminate between the 
populations (ROC = 0.578).   
Its addition with the 4 marker regression did increase the test performance in all categories (ROC = 
0.929, 0.875, 0.901). This final test had a sensitivity of 81.1%, specificity of 79.4%, PPV of 86.0%, and 
NPV of 72.9% (Figure 9). Perhaps this demonstrates a role for combination marker types in future 
testing.  
Figure 8 Combined DNA marker ROC curve. 
(Sensitivity = 81.1%, specificity = 75.8%, PPV = 84.3%, NPV = 71.4%). 
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Figure 9 Combined DNA marker plus CEA ROC curve. 
(Sensitivity = 81.1%, specificity 79.4%, PPV = 86.0%, NPV = 72.9%). 
 
4.6 Box plots and whisker analysis. 
Boxes represent 25th to 75th centiles and the internal black line the median value. The top whisker is 
the maximum SPSS accepted population value (< 1.5 Inter-quartile range (IQR) from the edge of the 
box). The bottom whisker is the minimum SPSS accepted population value (<1.5 (IQR) ). “O” is an 
outlier in population between 1.5 and 3.0 x IQR from the edge of the box.  “*” is an extreme outlier 
greater than 3.0 x inter-quartile range from edge of box. The scale on the Y axis is logarithmic to 
allow easier evaluation of the main populations. There are normal, polyp and cancer groups. 
Figure 10 CEA box plot analysis. 
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Figure 11 Total Nuclear DNA box plot analysis. 
 
Figure 12 Mitochondrial DNA box plot analysis. 
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Figure 13 Alu 155bp DNA box plot analysis. 
 
Figure 14  Alu 247bp DNA box plot analysis. 
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Figure 15 Line 1 300bp DNA box plot analysis. 
 
Figure 16 Line 1 79:300 DNA ratio box plot analysis. 
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Figure 17  Alu 115:247 DNA ratio box plot analysis. 
 
4.7 Correlation of Total cfDNA with age. 
Analysing the most uniform population (normal group), there was no significant correlation with age 
using both Spearman’s rho (P=0.07), and Kendalls tau b (P=0.09).  
Figure 18 Correlation of total cfDNA with age. 
 
4.8 Conclusions. 
 This study demonstrates highly significant differences between a “normal” population, a 
population with adenomatous polyps, and a population with colonic cancer.  
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 Quantities and patterns of circulating DNA differ significantly between the groups, with total 
quantities of nuclear and mitochondrial DNA increasing with pathological grade, and 
fragmentation patterns changing between normal, adenomatous and cancer populations.  
 Individual markers demonstrate good diagnostic tests, and in combination provide an 
improved test for both polyps and cancer (ROC = 0.888).  
 Although adding CEA levels to the combination DNA marker did improve the final diagnostic 
test for polyps and early cancer, ROC curve = 0.901.  It did not add greatly and the results are 
included largely to show that this marker, even in combination with others, has little 
diagnostic value. 
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Chapter 5 Oesophago-gastric results. 
5.1 Demographics. 
The study population comprised 115 patients, with 120 samples and includes: 35 patients without 
endoscopic abnormality; 9 patients with Barrett’s oesophagus; 13 patients with high grade dysplasia; 
12 patients with invasive cancers restricted to the mucosa (IMC); 3 patients with invasive cancers 
restricted to the sub-mucosa (SMC); and 43 patients with advanced cancers.  
 
The reference “normal” group consisted of nine biopsy proven benign Barrett’s oesophagus cases, 
and 35 patients representing a typical population attending for endoscopic investigation but with no 
detectable abnormality (Table 18). The mean age of the combined normal group was 56.1 years 
(range 24 - 80 years), and included 22 men (7 Barrett’s, and 15 normal endoscopy patients).  
Significant inter-current diagnoses in this group included: osteoarthritis; ischaemic heart disease; 
pernicious anaemia; and peptic ulcer. 
 
Table 18 Normal population indication for endoscopy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endoscopy indication 
Patient 
numbers 
Dysphagia 5 
Dyspepsia 10 
Ulcer follow up 1 
Haematemesis 2 
Abdominal pain 8 
Change in bowel habit 7 
Family history of cancer 1 
Anaemia 5 
Polyp follow up 1 
Melaena 1 
Barrett’s surveillance 9 
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5.2 Patient groups. 
Due to well documented difficulties accurately identifying Barrett’s dysplasia grades, the groups 
were combined into clinically relevant groups. These groups have a higher concordance for accurate 
differentiation pathologically319, 320. When pathological samples showed mixed grades the highest 
grade of dysplasia was used. The combined groups were “HGD and IMC”, and “SMC and cancer”. 
 
The HGD and IMC group consisted of 25 patients, 20 men, with a mean age of 70.0 years (range 54-
89 years). There were 30 samples, 15 each of HGD and IMC, six from patients with recurrent disease. 
The SMC and cancer groups consisted of 43 patients, 18 men, with a mean age of 68.9 years (range 
50-82 years). There were 46 samples, 3 from patients with superficial sub-mucosal invasive disease. 
Forty samples were from advanced cancers, staged by CT, EUS, and PET scanning as: 5 x T1N0M0, 16 
x T2/3N0M0, 4 x T2N1M0, 5 x T3N1M0, 1 x T4N1M1, 10 had metastatic disease and 2 had unclear 
staging prior to receiving palliative chemotherapy. The T0 and T1 cancers were deep sub-mucosal 
invading tumours. 
 
In total, both dysplasia and cancer populations include 68 patients, and 76 plasma samples, with a 
mean age of 69.5 years, (39 - 89 years). 
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5.3 Mean and median marker values. 
Table 19 Mean value for all markers. 
Mean values Total Mito 115 300 247 79/300 115/247 
"Normal" 10.8 1.1 35.6 1.8 3.1 6.3 11.0 
HGD + IMC 14.1 4.2 42.6 3.2 4.6 6.1 10.3 
SMC & Cancer 19.2 6.2 76.9 5.3 4.9 8.8 16.3 
 
 Table 20 Median value for all markers. 
Median values Total Mito 115 300 247 79/300 115/247 
"Normal" 7.3 0.7 24.9 1.5 2.7 5.1 9.5 
HGD + IMC 11.0 1.5 30.7 2.4 3.2 5.3 10.3 
SMC & Cancer 12.2 1.5 39.5 2.8 2.3 6.3 12.4 
 
Each marker was analysed between normal, HGD and IMC, and SMC and cancer populations (Tables 
19 and 20).  There was an increase in the mean values of all markers with increasing pathological 
grade except for the fragment ratios. Not all of these differences were statistically significant (Table 
21). 
5.4 Statistical significance - Mann Whitney U-tests. 
Applying a 10 fold Bonferroni correction, the significant P value = 0.005. 
 Table 21 Statistical significance testing. 
Mann Whiteny U-test P values Total Mito 115 300 247 79/300 115/247 
“Normal” vs  HGD + IMC 0.010 0.016 0.121 0.014 0.076 0.939 0.779 
“Normal” vs SMC & Cancer 0.013 0.000 0.003 0.004 0.448 0.180 0.180 
“Normal” vs all abnormal 0.003 0.000 0.006 0.001 0.715 0.121 0.086 
 
As compared with normal controls, patients with HGD and IMC did not have significantly raised 
levels of all markers, Table 21. 
 
As compared with normal controls, patients with SMC and oesophageal cancer had significantly 
raised levels of mitochondrial DNA (p=0.000), Alu 115bp (P<0.003), Line 1 300bp (P=0.004) Table 21. 
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Comparison of normal with all neoplasia patients showed that Total DNA (p=0.003), mitochondrial 
DNA (p=0.000), and Line 1 300bp (p=0.001) were highly significantly different between the 
populations.   
5.5 ROC curve values and Logistic regression. 
Table 22 ROC curve characteristics. 
ROC curve values Total Mito 115 300 247 79/300 115/247 
"Normal" vs  HGD + IMC 0.678 0.665 0.607 0.67 0.622 0.505 0.481 
"Normal" vs SMC & cancer 0.652 0.713 0.68 0.677 0.454 0.646 0.646 
"Normal" vs all abnormal 0.662 0.694 0.651 0.674 0.674 0.585 0.595 
 
The best single marker in the HGD and IMC population was Total DNA (ROC=0.678), with the 
combination DNA marker showing a fair diagnostic ability (ROC = 0.718) Table 22. 
The best single marker in the SMC and oesophageal cancer population was mitochondrial DNA 
(ROC=0.713), with the combination DNA marker showing a good diagnostic ability for distinguishing 
cancer from normal in this series (ROC = 0.847). The combination test had a PPV for invasive cancer 
patients of 81.1% and a NPV of 70.6% (Sensitivity = 61.3%, specificity = 83.7%) (Figure 19). 
The best single marker for diagnosis of all neoplasia in this population was Alu 115 mitochondrial 
DNA (ROC = 0.694), with the combination DNA marker showing a fair diagnostic ability (ROC=0.778). 
The combination test had a PPV for dysplasia and cancer patients of 78.2%, and a NPV of 65.0% 
(Sensitivity = 81.3%, specificity = 60.5%) (Figure 20). 
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Figure 19 Normal group vs. all invasive cancer group. 
 
Sensitivity = 61.3%, specificity = 83.7, PPV = 81.1%, NPV = 70.6%. 
Figure 20 Normal group vs. all abnormal oesophagus group. 
 
Sensitivity = 81.3%, specificity = 60.5%, PPV = 78.2%, NPV = 65.0%. 
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5.6 Box plots and whisker analysis. 
Boxes represent 25th to 75th centiles and the internal black line the median value. The top whisker is 
the maximum SPSS accepted population value (< 1.5 Interquartile range (IQR) from the edge of the 
box). The bottom whisker is the minimum SPSS accepted population value (<1.5 (IQR) ). “O” is an 
outlier in population between 1.5 and 3.0 x IQR from the edge of the box.  “*” is an extreme outlier 
greater than 3.0 x inter-quartile range from edge of box. There are normal, mucosal neoplasia and 
cancer groups. 
Figure 21 Total Nuclear DNA box plot analysis. 
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Figure 22 Mitochondrial DNA box plot analysis. 
 
Figure 23 Alu115bp DNA box plot analysis. 
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Figure 24 Alu 247bp DNA box plot analysis. 
 
Figure 25 Line 1 300bp DNA box plot analysis. 
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Figure 26 Line 1 79:300 DNA fragment ratio box plot analysis. 
 
Figure 27 Alu 115:247 DNA fragment ratio box plot analysis. 
 
5.7 Conclusions. 
 This study demonstrates highly significant differences in cfDNA between a “normal” 
population, a population with dysplasia and early cancer, and a population with invasive 
cancers.  
 Quantities of circulating DNA differ significantly between the groups, with total quantities of 
nuclear and mitochondrial DNA increasing with pathological grade. Mean and median 
fragmentation ratios increase through grades, which although not significant, may reflect a 
true change in populations. 
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 Although most individual markers demonstrate only fair  diagnostic tests, in combination 
they provide an improved test for both neoplastic groups and in particular provide a good 
test for advanced invasive cancers (ROC = 0.847). 
   
6-98 
 
Chapter 6 Paired colonic and oesophageal results. 
6.1 Introduction. 
This chapter looks at the feasibility of using cfDNA markers to judge whether a colonic or 
oesophageal lesion has been completely removed endoscopically. Current practice involves 
repeating the endoscopic assessment at 3, 6 and 12 monthly intervals. 
The markers will be measured before and after resection in pairs from the same patient. The paired 
samples will allow the statistically more powerful Wilcoxon signed rank test to be used. 
The mean pre and post-resection levels will also be compared to the control population using the 
Mann-Whitney test. This will analyse whether pre-resection patient levels and later post-resection 
levels are different from background control results. 
6.2 Colon results. 
6.2.1 Demographics . 
The paired samples came from 15 patients with an average age of 72 y, 7 men. 
6.2.2 Lesions. 
Pre-resection lesions included one polyp cancer, nine HGD polyps, and five LGD polyps. After follow 
up over 2 years 14 patients had been resected back to normal, and 1 patient had a small area of 
residual LGD polyp at the time of the last sampling.   
Only the fourteen samples with complete resection were analysed for statistical purposes. However, 
in the line graphs below, results included the sample with residual LGD dysplasia and an 
intermediate sampling result in a patient with residual LGD who went on to complete resection. 
These are included for comparison purposes. 
6.2.3 Mean results. 
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Table 23 below shows mean values for the patients with polyps before and after resection. To allow 
comparison the polyps group (pre-resection equivalent) and normal (post-resection equivalent) are 
included. 
Although the absolute values are difficult to interpret due to the small numbers, there is a consistent 
trend mirroring the differences between normal and polyp groups. 
Table 23 Paired means pre and post resection, and normal and polyps. 
Mean values 
CEA ng/ml 
plamsa 
Total DNA 
ng /ml 
plasma 
Mito 
ng/ml 
plasma 
Alu 115 ng/ml 
plasma 
Line 300  
ng/ ml 
plasma 
Alu 247 ng/ml 
plasma 
79/300 115/247 
Polyps group 0.7 16.1 2.9 74.4 4.4 5.5 6.4 18.0 
Normal group 0.5 8.6 0.9 24.6 1.6 2.8 6.4 8.3 
Pre-resection 0.80 33.58 8.27 101.07 26.06 20.53 3.63 14.96 
Post-resection 0.75 12.89 6.55 51.49 1.78 5.36 7.09 10.96 
 
6.2.4 Significance testing. 
Paired sample values pre and post-resection were tested with the Wilcoxon signed rank test, non-
paired comparisons against the control group and were tested with the Mann-Whitney statistic. 
Applying a 10 fold Bonferroni correction, the significant P value = 0.005. 
Table 24 Significant P values.  
 P values 
CEA ng/ml 
plamsa 
Total DNA 
ng /ml 
plasma 
Mito 
ng/ml 
plasma 
Alu 115 
ng/ml 
plasma 
Line 300  
ng/ ml 
plasma 
Alu 247 
ng/ml 
plasma 
79/300 115/247 
pre vs post-resection  0.637 0.551 0.433 0.331 0.005 0.875 0.001 0.272 
 pre-resection vs normal 0.048 0.025 0.004 0.000 0.001 0.049 0.013 0.046 
post-resection vs normal 0.064 0.138 0.347 0.028 0.507 0.020 0.127 0.785 
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6.2.5 Individual markers. 
6.2.5.1 CEA analysis. 
There are no significant differences between the polyp CEA levels, before and after resection (P > 
0.048). Moreover the trend does not decrease towards normal levels and the illustration below 
shows this (black lines represent cases resected back to normal, and red broken lines cases not 
resected back to normal).  This confirms the opinion that CEA is a poor diagnostic marker. 
Figure 28 Paired CEA values pre and post resection. 
 
6.2.5.2 Line 1 79bp - total cfDNA. 
There are no significant differences between the polyp total DNA levels, before and after resection 
(P > 0.025). However, the trend does decrease towards normal levels and the illustration below 
shows this. 
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Figure 29 Paired total cfDNA values pre and post resection. 
 
6.2.5.3 Mitochondrial cfDNA. 
There are no significant differences between the patients’ mitochondrial DNA levels before and after 
resection. However, when comparing pre-polyp levels to the control population there is a significant 
difference ( p=0.004). Post resection levels are not significantly different to the normal population 
(p=0.347). The illustration below shows this, although not all cases follow this pattern. 
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Figure 30 Paired mitochondrial cfDNA values pre and post resection. 
 
6.2.5.4 Alu 115bp  fragment. 
There are no significant differences between the patients’ Alu 115bp DNA levels before and after 
resection. However, when comparing pre-polyp levels to the normal population there is a significant 
difference (p=0.000). Post resection Alu 115bp levels are not significantly different to the normal 
population (p=0.028). The illustration below shows this, although not all cases follow this pattern. 
Figure 31 Paired Alu 115bp values pre and post resection. 
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6.2.5.5 Line 1 300bp fragment. 
There are significant differences between the patients’ Line1 300bp DNA levels before and after 
resection of their polyps (p=0.005). When comparing pre-polyp DNA levels to the normal population 
there is also a significant difference (p=0.001). Post resection levels are not significantly different to 
the normal population (p=0.507).The illustration below shows this, although not all cases follow this. 
Figure 32 Paired Line 300bp values pre and post resection. 
 
6.2.5.6 Alu 247bp fragment. 
There are no significant differences between the polyp total DNA levels, before and after resection 
(P > 0.020). However, the trend does decrease towards normal levels and the illustration below 
shows this. 
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Figure 33 Paired Alu 247bp values pre and post resection. 
 
6.2.6 Marker ratios. 
6.2.6.1 Line 1 79:300. 
There are significant differences between the patients’ Line 1 79/300bp ratio levels before and after 
resection of their polyps (p=0.001). However, when comparing pre-polyp Line 1 79/300bp ratio 
levels to the normal population there is no significant difference (p=0.013), and therefore the 
analysis of this marker is uncertain. 
Post resection Line 1 79/300bp ratio levels are not significantly different to the normal population 
(p=0.127), and therefore the mixed results reflect the poor diagnostic usefulness of this marker 
when used alone. 
The illustration below does show a clear change in ratio with resection, which would be in keeping 
with the theories of circulating DNA origins reflecting the fall in the amount of apoptotic long 
fragment DNA. Perhaps this explains in part why this marker is helpful in combination with other 
markers. 
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Figure 34 Paired Line 1 79:300 ratio values pre and post resection. 
 
6.2.6.2 Alu 115:247. 
There are no significant differences between the polyp Alu 115/247bp ratio levels, before and after 
resection (P > 0.046). However, the trend does decrease towards normal levels and the illustration 
below shows this. 
The illustration below shows a mixed picture but there are only a few cases that rise. Interestingly, 
the fall in ratio is the exact opposite of the Line 1 ratio above, but does mirror the trend in the polyp 
and cancer groups compared to normal patients. Looking at the results the large Alu 247bp fragment 
levels do fall.  
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Figure 35 Paired Alu 115:247 ratio values pre and post resection. 
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6.3 Oesophageal results. 
6.3.1 Demographics . 
The paired samples came from 14 patients, 12 men, with an average age of 66.3 years.  
6.3.2 Lesions. 
Pre-resection lesions included 4 SM1 invasive cancers, 3 IMC lesions, and 7 HGD.  
After follow up over 2 years 8 patients had been resected back to normal Barrett’s, 1 patient later 
developed  carcinomatosis of unknown primary, 1 patient  had a residual IMC lesion, 3 patients had 
residual HGD lesions, and 1 patient developed a LGD lesion.  
Post resection diagnoses were made by an experienced endoscopist using specialist dye spray 
techniques and gold standard biopsy practice. Biopsy specimens and resection samples were 
reviewed by two experienced pathologists. 
Only the eight samples with complete resection back to normal Barrett’s were analysed for 
statistical purposes. However, in the line graphs below results included the other samples for 
comparison purposes. The sample pair with residual LGD dysplasia sample was represented as 
normal due to the difficulties discriminating LGD from inflammation in specimens. 
6.3.3 Mean results. 
Table 25 below shows mean values for patients with neoplastic Barrett’s lesions before and after 
resection. To allow comparison the mucosal neoplasia group (pre-resection equivalent) and control 
group (post-resection equivalent) are included. 
Although the absolute values are difficult to interpret due to the small numbers, there is little if any 
pattern or difference visible. 
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Table 25 Paired means pre and post resection, and control and mucosal neoplasia. 
Mean values 
Total DNA    
ng /ml 
plasma 
Mito 
ng/ml 
plasma 
Alu 115 
ng/ml 
plasma 
Line 300  
ng/ ml 
plasma 
Alu 247 
ng/ml 
plasma 
79/300 115/247 
Mucosal neoplasia group 14.1 4.2 42.6 3.2 4.6 6.1 10.3 
Control group 9.88 0.99 34 1.7 2.83 6.3 11.1 
Pre-resection 12.36 1.57 32.17 2.23 3.57 7.94 9.36 
Post-resection 14.04 0.98 37.08 2.57 6.41 6.42 6.35 
6.3.4 Significance testing. 
Paired sample values pre and post-resection were tested with the Wilcoxon signed rank test, non-
paired comparisons against the control group and were tested with the Mann-Whitney statistic. In 
keeping with the mucosal neoplasia group in chapter 5 there are no markers that are significantly 
different to the control population results. 
Applying a 10 fold Bonferroni correction, the significant P value = 0.005. 
Table 26 Significant P values. 
P values 
Total DNA 
ng /ml 
plasma 
Mito 
ng/ml 
plasma 
Alu 115 
ng/ml 
plasma 
Line 300  
ng/ ml 
plasma 
Alu 247 
ng/ml 
plasma 
79/300 115/247 
pre vs post-resection  0.859 0.515 0.314 0.260 0.594 0.110 0.678 
pre-resection vs 
normal 
0.041 0.251 0.522 0.293 0.339 0.586 0.748 
post-resection vs 
normal 
0.032 0.679 0.517 0.422 0.006 0.312 0.101 
 
6.3.5 Individual markers. 
6.3.5.1 Line 1 79bp - total cfDNA. 
There are no significant differences between the patients’ total DNA levels before and after 
resection (P > 0.032). The illustration below shows a general reduction in levels but unfortunately 
total DNA is not a good measure of completeness of resection. 
(Black lines represent cases resected k to normal, and red broken lines cases not resected to normal)  
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Figure 36 Paired total cfDNA values pre and post resection. 
 
6.3.5.2 Mitochondrial cfDNA. 
There are no significant differences between the patients’ mitochondrial DNA levels before and after 
resection (P > 0.251). The illustration below shows a mixed picture. 
Figure 37 Paired mitochondrial cfDNA values pre and post resection. 
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6.3.5.3 Alu 115 fragment. 
There are no significant differences between the patients’ Alu 115bp fragment DNA levels before 
and after resection (P > 0.314). The illustration below shows a mixed picture. 
Figure 38 Paired Alu 115bp values pre and post resection. 
 
6.3.5.4 Line 1 300bp fragment. 
There are no significant differences between the patients’ Line 1 300bp fragment DNA levels before 
and after resection (P > 0.260). The illustration below shows a mixed picture. 
Figure 39 Paired Line 1 300bp values pre and post resection. 
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6.3.5.5 Alu 247bp  fragment. 
There are no significant differences between the patients’ Alu 247bp fragment DNA levels before 
and after resection, although it is the best test (P > 0.006). The illustration below shows mainly an 
increased level of the “apoptotic” fragment post resection, which doesn’t fit the explanations given 
for the origin of circulating DNA. This result needs to be treated cautiously. 
Figure 40 Paired Alu 247bp values pre and post resection. 
 
6.3.6 Marker ratios. 
6.3.6.1 Line 1 79:300. 
There are no significant differences between the patients’ Line 1 79/300bp fragment ratio before 
and after resection (P > 0.110). However, the illustration below shows a mainly decreased level 
regardless of resection, which may illustrate why it adds diagnostically as part of the multi-marker 
model. 
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Figure 41 Paired Line 1 79:300 ratio values pre and post resection. 
  
6.3.6.2 Alu 115:247. 
There are no significant differences between the patients’ Alu 155/247bp fragment ratio before and 
after resection (P > 0.101). The illustration below shows a mixed picture. 
Figure 42 Paired Alu 115:247 ratio values pre and post resection. 
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6.4 Conclusions. 
 The number of paired samples resected to normal in colonic and oesophageal neoplasia 
cases is small, making interpretation difficult.  There are occasional trends, and these data 
warrant larger studies in both cancer types. 
 In colonic neoplasia the Line 1 300bp marker is significant different in the paired and non-
paired analysis. This appears to confirm its diagnostic role in colonic neoplasia and suggests 
it may be feasible to use this as a measure of endoscopic polyp resection.  
 The other markers mirror the results in chapter 4, but are not significant. This pattern is 
confirmed by the graphical illustrations which suggest that the total DNA, mitochondrial 
DNA, Alu 115bp fragment, Alu 247bp fragment, and Line 1 79/300bp fragment ratio may be 
helpful in the diagnosis of colonic neoplasia. 
 In oesophageal neoplasia the best marker is the Alu 247bp marker which approaches 
significance (P=0.006), but the result appears to confound current understanding of cfDNA 
origins. The graphical illustrations suggest that the Line 1 300bp and Line 1 79/300bp 
markers may be helpful in a larger oesophageal neoplasia study.  
 Overall the oesophageal results reflect those in chapter 6 where no marker was significantly 
different when comparing mucosal neoplasia to the control group. It seems unlikely that 
these markers will help to judge complete endoscopic removal. 
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Chapter 7 Discussion and conclusions. 
Colorectal and oesophageal cancer carry a high mortality in the UK, and efforts to diagnose the 
disease at an earlier stage are regarded as key to reduce associated deaths54.  Current diagnostic 
approaches have problems with poor sensitivity and low acceptability. This study was undertaken to 
try and find markers to identify early cancer and thereby address these issues. 
cfDNA shows potential as an early cancer marker with  Alu 115bp, Alu 247bp, Line 1 79bp, Line 1 
300bp and mitochondrial DNA sequences previously shown to be raised in populations with 
advanced cancer.   
Using improved techniques, this study tested the hypothesis that patients with pre-cancerous 
change and early cancers also have significantly different cfDNA levels and ratios when compared to 
control or “normal” populations. As part of this study, levels of the markers were tested before and 
after endoscopic resection to act as a marker for completeness of endoscopic resection. 
 This chapter reviews the individual results and discusses them in the context of the circulating 
biomarker literature, the origins of cfDNA, and the potential role as a diagnostic test for colonic and 
oesophageal cancers. The current evidence based approaches to the collection and processing of 
specimens will also be reviewed. 
7.1 Control population results. 
The patients in the control group have symptomatic benign gastrointestinal disease, and normal 
investigation. With a mean age of 54.1 years they represent an “at risk” group for colorectal and 
oesophageal cancer and therefore are a good clinical control group. 
The total amount of cfDNA in the control population in this study was 10.8 ng/ml of plasma , 
comparable to a study of normal population baselines reporting 16 ng of cfDNA/ml of whole blood. 
Age does not seem to affect cfDNA levels 124. 
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Included in the oesophageal control group were patients with Barrett’s oesophagus. This is 
important if the test is to have a clinical role. Although the number of these patients was small there 
was no significant difference in the individual marker results, except the ratio marker Alu 115/247bp. 
In the context of non-significant individual markers this is suspicious for a type I error. Further 
testing will be needed to confirm this.  
Reservations regarding the utility of cfDNA markers in discriminating the normal population have 
been expressed.  An ovarian cancer study included a population of patients admitted to hospital for 
treatment of benign diseases and these formed part of the control group.  Results from this control 
group showed raised cfDNA levels reaching 16 ng/ml of plasma. It was therefore concluded that 
cfDNA has reduced diagnostic accuracy170. However, these ‘benign’ conditions included patients 
admitted to hospital with infections, autoimmune disease, post organ transplant, post-trauma, AIDS, 
and asthma.  These conditions are likely to be associated with active inflammation and increased 
apoptosis which cause proven increases in circulating DNA103, 107, 113, 164. Inflammation in a study of 
circulating DNA nucleosomes shows a clear correlation with DNA levels174. Such severely ill patients 
are unlikely to be represented in large numbers within the population attending screening visits and 
would be rapidly removed from the test pool.  We therefore believe that in our group of patients 
confounding factors such as inflammatory lesions would be picked up through the clinical history 
and treated separately and that cfDNA could still be a good marker for differentiating between 
normal and cancer groups.  
In a single patient with Barrett’s oesophagus the cfDNA level was surprisingly high with a total DNA 
of 78ng/ml. The reason for this patient’s results are not clear; the patient was losing weight and had 
transfusion dependent anaemia. A similar statistically outlying patient with a high DNA level of 
47ng/ml had an unexpected pancreatic cancer found. 
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 It may be that in the 1st patient a similar diagnosis will eventually be made. These cases 
demonstrate both the strength of measuring cfDNA as a test for cancer, and the problems that 
clinicians may face when a positive cfDNA result leads to a negative clinical test.  
For the purposes of this study the first patient was included but the second patient was excluded.  
7.2 Colonic results. 
Screening for colorectal cancer is challenging with the diagnosis of pre-cancerous adenomatous 
polyps regarded as essential for the prevention of cancer, and yet they represent a more difficult 
diagnostic target.  
This study demonstrated highly significant differences between the control population, the 
population with adenomatous polyps, and the population with colonic cancer.  
Quantities and patterns of circulating DNA differed significantly between the groups, with total 
quantities of nuclear and mitochondrial DNA increasing with pathological grade, and fragmentation 
patterns changing between normal, adenomatous and cancer populations. Test results showed that 
the markers individually acted as good markers of disease and that in combination they provided an 
improved test for both polyps and cancer with a ROC = 0.888. To our knowledge this is the first study 
to demonstrate significant differences in circulating DNA in colonic polyps and cancer patients and 
offers the prospect of improved diagnosis of neoplasia in colorectal cancer screening with a simple 
blood test.   
However, overlapping results with false positives in normal patients, and false negatives in 
neoplastic patients needs some work. The false positive patients with an excess of cfDNA seem likely 
to result from initial storage and processing issues, artefactual haemolysis and white cell lysis, or 
confounding sub-clinical disease. 
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 A stricter approach to sampling, a visual and microscopic assessment for haemolysis and careful 
patient questioning with prospective CRP testing to exclude patients with inflammation (CRP>5) 321 
may help avoid this. False negative testing may prove more difficult but prospective testing with 
limited storage and careful processing without cell separation or filtration may help. Tumour sizes, 
pathological differentiation, and proliferation measures were not used in this study and may 
influence the results e.g. small and well differentiated tumours with low proliferation rates may 
produce low cfDNA levels. Further studies looking at oxidised or methylated 98, 182, 211 cfDNA levels 
may help sensitivity and specificity for cancer, with assessment of hypermethylated foetal cfDNA in 
the maternal blood circulation showing the possibilities322. 
Although total cfDNA levels differed significantly between the polyps and cancer groups within the 
polyp population neither size, nor estimated surface area showed significant correlation with cfDNA 
in both the total polyp population (p=0.28) and the larger category of LGD polyps (p=0.24). Perhaps 
surprisingly there was also no significant difference in total cfDNA levels (p=0.926) or size between 
the LGD (52.5mm) and HGD (51.9mm) polyps. Accurate sizing and grading of polyps is difficult with 
lateral and outward growth contributing to an overall volume, and small foci of HGD dictate polyp 
categories. Therefore although we have found no differences in cfDNA with size or grade of polyp it 
is difficult to be entirely confident that they are not relevant to cfDNA levels. It seems reasonable to 
group polyps together, and it will be difficult to get a clearer answer. 
Whilst a larger population would have been desirable, these results arise in a clinically relevant 
population. Results from other studies also provide good support for our findings.  A study published 
in 2009 in abstract form only, confirmed the significance of the 115bp and 247bp Alu marker 
changes in early and late colorectal cancer patients in plasma. However, results in patients with 
polyps were not significantly different to the “clean-colon healthy subject” control population 323. 
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  No details of sample processing methodology were included and so interpretation of the true 
negativity of this study is difficult. Perhaps our results reflects the small fragment cfDNA and spin 
protocols used. The polyps in our population were also unusually large and although in our analysis 
size was not found to correlate with DNA levels, this may have contributed to our positive findings. 
A paper published in 2006 also demonstrated strikingly similar DNA levels to our findings, although 
in serum. The study looked at more advanced colon cancers and showed a healthy control group 
with an almost identical median total DNA level of 7.7 ng/ml (current study - 6.86 ng/ml). CfDNA 
levels in cancer patients was 35.8 ng/ml compared to   14.58 ng/ml) in this study. A combined 
diagnostic ROC score discriminating cancer cases was 0.92. 242.  
In other cfDNA studies the fragment ratio was the most sensitive diagnostic marker89, 94, 115, 149, 165, 
however it is unclear whether DNA integrity of all genes is significant as two studies found negative 
results166, 324. In our colonic results there were significant differences in the colonic ALU 115/247bp 
fragment ratio, and the ratio results did add to the 4 marker DNA regression analysis. However, the 
fragmentation ratio was not the most sensitive marker in our study possibly suggesting that it acts as 
a more sensitive marker in advanced cancers.  
Mitochondrial DNA, with multiple copies in each cell, has been proposed to provide a more accurate 
marker in the analysis of low quantities of circulating DNA. In agreement with this, our colonic 
results showed highly significant differences between the groups with a rise in benign and cancer 
groups. However, in logistic regression analysis it did not add to the accuracy obtained with nuclear 
cfDNA markers, and other studies have reported both high and low levels in cancer325-327. We did not 
use it as a marker for our final analysis because of this.   
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cfDNA quantification and Alu 247 fragment results have now been demonstrated to be consistent 
across serum studies in both non-inflammatory normal patients, three types of gastro-intestinal 
cancers149, 157, 328 and breast cancer115.  We believe that they offer the prospect of a broad neoplasia 
screening test in non-inflammatory cancers. This approach would be highly attractive to patients, 
although greater specificity for cancer type would be required.  Differentiating between cancers 
however may be possible from other tests, even using the same blood sample.  For example, in our 
study the 300bp marker did not perform well, but this fragment did show promise in breast cancer147. 
The different DNA patterns may help identify gastrointestinal cancers and differentiate them from 
other cancer types e.g when the Alu 247 bp fragment is raised. This interesting finding may relate to 
the biological handling of cfDNA from the digestive system before it enters the normal circulation329, 
330, and may give the Alu 247 bp fragment a degree of specificity for colorectal neoplasia. 
Alternatively specificity may be achieved by using additional PCR markers such as methylated Septin 
9, or ELISA based assays with Colon Cancer Specific-2, or TIMP 1 proteins177, 187, 268, 278. This may allow 
combinations similar to the CEA results in our study offering the prospect of a more specific blood 
test screen for colorectal cancer.  In our study, CEA did not add greatly to the ROC, and the results 
are included to show that this marker, even in combination with others, has little diagnostic value. 
Mitochondrial fragments with highly significant results across both studies and high individual ROC 
values (0.742, 0.694) may also offer a broad neoplasia screen. Previous studies have shown 
significant findings discriminating testicular and breast cancer 173, 212, 326, and mitochondrial cfDNA 
also has promise as a universal neoplasia marker.  
Alternatively, cfDNA may be a useful triage test for patients with a positive faecal occult blood test.  
Those with cfDNA below a threshold defined by the ROC curve could be spared the risk and cost of 
colonoscopy  
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In 2010 a study sequenced all circulating cfDNA in breast cancer patients. Alu and line were 
significant markers which in combination with others gave sensitivity (90%) and specificity (95%) in 
breast cancer patients208. This should give a more complete answer and looks a promising approach 
for the future. 
7.3 Oesophageal results. 
Screening for oesophageal cancer is especially challenging even in those diagnosed with Barrett’s 
oesophagus. The diagnosis of pre-cancerous dysplasia and early cancer is essential to improve the 
prognosis and represents a very challenging diagnostic target.  
This study demonstrates highly significant differences between the control population, a population 
with invasive cancers, and a combined population with mucosal neoplasia and invasive cancers. 
Quantities and patterns of circulating DNA differ significantly between the groups, with total 
quantities of nuclear and mitochondrial DNA increasing with pathological grade, and fragmentation 
patterns changing between control and invasive cancer populations. 
Although most individual markers are only moderately successful as diagnostic tools, in combination 
they provide an improved test.  In particular they provide a good test for advanced invasive cancers 
(ROC = 0.859), although of course the clinical problem is to detect patients before they reach this 
stage.  
Comparing cfDNA levels from oesophageal neoplasia patients to those form colorectal patients it is 
apparent that all sample levels are broadly lower except for mitochondrial DNA. With at least some 
of the blood by-passing the liver circulation this is surprising. Why oesophageal cancers should 
produce less cfDNA is unclear. Technically some of the plasma samples were stored for over 2 years 
reflecting the relative rarity of mucosal Barrett’s neoplasia samples. 
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 A previous study has shown that cfDNA levels decrease with time in storage even at -80 °C331, and 
some of the neoplasia samples may have suffered because of this. The Low levels of cfDNA in the 
cancer group however remain unexplained. They were collected towards the end of the study and 
stored for less than 1 year. As discussed in the colon results above, false positives and false negatives 
will need to be addressed. The strategies suggested may also help with the low DNA levels found 
with the oesophageal samples. 
When the results were analysed without including both normal Barrett’s oesophagus outlier samples, 
suspicious for underlying cancers, the mean results for line 1 79 bp, Line 1 300 bp, Alu 115 bp and 
Alu 247 bp fragments were all significant at p =  0.001. The ROC value, discriminating controls from 
all abnormalities was also 0.809, perhaps showing more clearly the potential for this type of testing.  
To our knowledge this is the first study to demonstrate these circulating DNA changes in 
oesophageal dysplasia and oesophageal adenocarcinoma, offering the prospect of improved 
diagnosis of neoplasia with a simple blood test.  While the test lacks specificity for oesophageal 
cancer, it could be particularly useful as a triage test for patients with Barrett’ s oesophagus. Those 
with cfDNA below a threshold defined by the ROC curve could be spared the risk and cost of 
oesophagogastroscopy.  
Alternatively specificity for oesophageal adenocarcinoma may be available from other tests, which 
could be performed on the same blood sample following an abnormal result.  Methylated APC or 
LOH at microsatellite markers202, 332 may begin to offer this.   
Sequencing and analysis of all cfDNA may be the ultimate diagnostic approach in oesophageal cancer, 
giving both sensitivity and specificity. Further studies are required however. 
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Whilst a larger population would be desirable, these results arise in a clinically relevant population 
with other results providing good support for our findings. Similar DNA levels in plasma from a study 
of more advanced mainly oesophageal adenocarcinomas show a healthy control group with an 
almost identical median total DNA level of 10 ng/ml (current study  7.3  ng/ml), and resectable 
cancer patients with 25 ng/ml (current study 12.2 ng/ml) 333.  In the above study cfDNA was 
compared retrospectively to CEA (cut off level of 5 ng/ml) as a detector of recurrent disease, cfDNA 
detecting 100% of recurrences and CEA detecting only 33%. CEA continues to show little clinical use. 
Mitochondrial DNA in our study rises in dysplastic and cancer groups showing highly significant 
differences in the cancer group. In logistic regression analysis it is the best single marker, although 
once again it adds little to the 4 DNA marker in common with colon cancers.  Mitochondrial DNA, 
Total DNA and Line 1 300 fragments are significant in our colonic and oesophageal results as well as 
breast cancer. Results in other cancers and our colonic series with the Alu 247 bp suggests these 4 
markers offer the best cfDNA prospect of a broad neoplasia screening test in cancers.  
The oesophageal fragment ratio results are not significantly different between the groups, which is 
disappointing and surprising. A study of squamous oesophageal cancers showed a significant 
difference (P=0.001), albeit against healthy controls, and other studies with adenocarcinoma have 
also been positive. Perhaps the long DNA storage once again contributed to the loss of DNA 
fragments in particular. It is noteworthy however that on removing the 2 outlier cases of normal 
Barrett’s oesophagus disease the results showed significant differences between the groups and this 
does need to be examined further.  
In conclusion cfDNA markers offer an interesting prospect for a blood test screen in oesophageal 
cancer, with our results showing the possibilities in early oesophageal cancer and pre-cancerous 
dysplasia. We have identified a combination marker in our population able to discriminate control 
patients with common medical problems from patients with dysplasia and invasive cancers, though 
this requires validation in a larger independent series. 
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7.4 Paired results. 
The number of cases with paired samples resected to normal in colonic and oesophageal neoplasia 
patients is small, making statistical interpretation difficult. 
In colon paired cases there is fall in Alu 247 bp fragment quantity and 115 bp / 247 bp ratio which 
although non-significant is similar to a study of patients who responded to radiotherapy for rectal 
cancer157. In colonic neoplasia the Line 1 300 bp marker is significantly different in the paired and 
non-paired analysis. This appears to confirm its changing level in colonic neoplasia and suggests even 
without a second validating series that the statistically significant results are correct. 
 The oesophageal paired data showed little change, and were not significantly different to normal. 
Clinically this reflects the fact that only mucosal disease is resectable and mirrors the results from 
the larger unpaired mucosal neoplasia data (P > 0.10). Disappointingly the resected samples did not 
return to normal values. Whether this is a sample size issue, a reflection of underlying abnormal 
tissue remaining, or whether there is ongoing inflammation post resection is unclear. There are no 
studies available to clarify this. 
Statistically the Alu 247 bp marker is the only marker approaching significance (P=0.006), but with 
the levels rising after resection and confounding current understanding of cfDNA origins this 
significance should be treated cautiously.  
Graphical analysis of the samples resected shows that nearly all of the Line 1 300bp and Line 1  
79/300 bp markers change in similar ways, and these may be helpful in a larger colonic neoplasia 
study. (Black lines = specimens resected back to normal, red broken lines = not fully resected to 
normal) 
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Figure 43 Paired Line 1 79:300 ratio values pre and post resection. 
 
Figure 44 Paired Line 1 300bp values pre and post resection. 
 
Overall, the colonic and oesophageal paired results are disappointing, and it seems unlikely these 
markers will help to judge complete endoscopic removal. 
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7.5 Sample processing. 
Within the study timescale, new research and equipment has been developed. Increasing evidence 
of the need to collect smaller DNA fragments137, 334 has led to the industry creating new specialist kits 
with Quiagen and nucleospin being the first two. With fast, reproducible, and standardized 
techniques these kits should be considered the gold standard. 
Studies looking at the effects of storage times on plasma samples have shown increased DNA levels 
after 2-6 hours, presumably from haemolysis at the time of sampling. Processing of samples in less 
than 2 hours is optimal and should prevent genomic DNA contamination153, 308. Haemolysis of 
samples is not entirely time related and it is important to avoid this through careful blood sampling.  
A double spin protocol to separate cells from plasma without the use of filtration and histopaque is 
optimal 153, 309, 310.  A further fast spin on thawing plasma prior to separating cfDNA is recommended 
by the manufacturer, making a triple spin protocol comprehensive. 
DNA degradation occurs at a fast rate even at -80°C. An extended collection period over 2 years is 
not recommended331.  Testing prospectively is recommended however where this is not possible 
storage in optimal buffers at temperatures < -80°C, with minimal freeze thaw cycles is best 210, 335. 
7.6 Implication for the origins of circulating DNA. 
In control patients the cfDNA level of the Alu 115 bp sequence is much greater than would be 
expected. When we observe the results of the Line 1 79 bp product (8-10ng/ml) in comparison to 
the Alu 115 bp product (25-35 ng/ml), both measured against the same genomic standard curve, we 
see that the Alu product is 3 times more abundant. If cfDNA was to arise from apoptosis and 
necrosis of normal cells then the relative quantities of Alu and Line 1 sequences should be 1:1. 
Therefore simple apoptosis and necrosis leading to release of cfDNA cannot explain this 
phenomenon.   
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Previous comparisons of Alu to β-globin gene sequences in cfDNA have shown similar results and 
active secretion of Alu sequences was therefore proposed336. DNA excretion has also been observed 
in differing in vitro-experiments and the phenomenon seems likely to play a significant role in cfDNA 
generation 337, 338. 
Quantities of both Line 1 79 bp and Alu 115 bp cfDNA sequences increase in cancer and pre-
cancerous patients but the reason for this unclear. If as traditionally proposed increased apoptosis 
and necrosis of neoplastic cells occurs then the ratio of Alu 115 bp to Line 1 79 bp should be lower or 
unchanged. Apoptosis or necrosis of normal cells should reduce the ratio. However, further 
increases in the Alu 115 bp :  Line 1 79 bp sequence (4:1) in both the oesophageal and colorectal 
cancer series suggests that the phenomenon leading to this unexpected ratio increases.  
Paired results also demonstrate sudden changes in cfDNA levels in early cancers in the same patient. 
This seems unlikely to be secondary to increased apoptosis and necrosis of the tumour or 
surrounding normal cells (figure 45).  
Figure 45. DNA quantities in a patient with progressive oesophageal cancer. 
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With an oesophageal cancer study showing little change in cfDNA cancer levels until metastatic 
disease is present , it is hard to see how increased apoptosis and necrosis can explain  cfDNA 
levels339. 
Perhaps these changes reflect a loss of cellular control as well as active secretion, with increased 
retro-transposon activity reflecting and even contributing to the cancer process340, 341 .  Line 1 and 
Alu sequences are both produced by retro-transposon activity, although only the long Line 1 
sequence is able to self replicate. Alu relies on Line 1 activity but is much shorter and therefore 
quicker to replicate. Increased retro-transposon activity may explain both the overall increasing 
quantities of Alu and Line 1 cfDNA sequences, and the increasing ratio of Alu to Line 1. 
Alternatively this may reflect an increased immune response to the cancer cells, with evidence for 
white cell activation leading to increasing DNA excretion. However, why the DNA excreted should be 
high in Alu sequences is unclear 342. 
Finally although a phenomenon such as secretion of DNA is necessary to explain the observed ratios 
and types of cfDNA sequences in these experiments, apoptosis and necrosis of neoplastic and 
normal cells may still contribute. This complex system would explain the observed increases in 
cfDNA, the “ladder phenomenon”, and the changing Alu and Line 1 levels. 
7.7 Diagnostic testing. 
While there is undoubtedly a rise of cfDNA in cancer patients, current results are not clinically 
sensitive or specific enough. Improved processing may help sensitivity and allow a screening 
approach to be developed, but the problems raised by lack of specificity for cancer sub-type remain. 
Validation of these results in a second population is required. In particular the ability to 
prospectively select normal patients from their given test result needs to be proven especially in 
light of the confounding presence of inflammatory conditions.   
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If the results prove reliable then a clinical use for this test may arise. The most obvious role for 
quantitative cfDNA testing is in screening for cancers, where a negative result may avoid further 
expensive and invasive tests. Importantly our results show changes in cfDNA in dysplasia samples 
compared to control groups which is an important and new finding, and a pre-requisite for screening 
an asymptomatic population. Barrett’s patients in particular with negative results may be able to 
avoid the unpleasant bi-annual endoscopy and biopsy.  
Identification of new additional markers, or a combination of old and new markers may provide a 
more specific and clinically useful test. Perhaps quantitative study of oxidised or hyper-methylated 
cfDNA will add sensitivity, or perhaps next generation sequencing techniques looking at all cfDNA 
sequences will provide a breakthrough. 
7.8 Conclusions. 
In conclusion, this study has shown that nuclear and mitochondrial cfDNA sequences are clearly 
raised in colonic and oesophageal dysplasia and cancer, which are new and important findings.  
We have identified that a combination of markers used in our population could discriminate control 
patients with common medical problems from patients with pre-cancerous changes and operable 
cancers. The ROC curves show that these markers present a good to excellent discriminating test, 
though this requires validation in a larger independent series.  
These results demonstrate the possibility of using cfDNA to screen for asymptomatic and 
unrecognized cancers using a simple blood test although further specificity or a negative test 
approach will be required. 
 Our results seem incongruous with the established hypothesis that apoptosis and cellular necrosis 
causes escape of cfDNA. The exact mechanism is still unclear but perhaps loss or change in the cells 
usual control processes allows increased DNA replication and subsequent overspill into the 
circulation.  
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Addendum 
Reflections after Viva Voce examination 
If cfDNA testing is to have a diagnostic or prognostic role it is important to understand the intra-
individual test variability in control and cancer patient cfDNA levels over time. The body has clear 
diurnal changes in hormone and metabolic profiles and the processes leading to cfDNA are also likely 
to be dynamic. Although in a steady state situation the cfDNA level appears homeostatically 
controlled118, 119, perhaps reflecting the situation in the normal population. In cancer patients the 
cfDNA levels are clearly changed and therefore homeostatic regulation of cfDNA cannot be assumed. 
Studies with repeat sampling at the same point in time and hourly sampling over a day are needed 
to further understand this. Work is also needed to understand the best time of day to sample cfDNA. 
With these results it should be possible to determine the number and timing of samples required for 
testing and the possible variation of individual cfDNA levels. 
Finding a role for cfDNA in staging cancers and predicting prognosis is hopeful, in what is a clinically 
challenging area. There are some promising studies already published98, 106, 114, 159, 178, 273, 343-346. 
However, in common with the diagnostic caveats above, further systematic study of cfDNA patterns 
in patients with pre-cancerous changes through to invasive and metastatic disease is required. 
Analysis of individual cfDNA levels at multiple time points through the disease stages will be needed 
to confirm and validate this. The confirmation of these findings will also serve to validate the cfDNA 
diagnostic approach.  
Oesophageal dysplasia is a relatively rare finding with agreement on pathological grading and 
staging being challenging319, 320. Particularly in this disease longitudinal follow up over 5-10 years will 
be important to confirm the initial grade and stage which informed the cfDNA studies. The average 
follow up in these patients for this thesis is 276 days and this may not be long enough.  
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Perhaps even before these studies are undertaken work to confirm processing outcomes and 
process timings is needed so that standardisation of techniques can occur. There has been some 
work towards this153, 309, 310.  
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Example of experimental amplification curves - Line 1 79bp 
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Raw data - sample set up line 1 79bp 
Block 
Type 
 
96fast 
      Chemistry 
SYBR_GREEN 
     Experiment File Name 
C:\Applied Biosystems\7500\experiments\experiments\Line 1 79\experiment results.eds 
Experiment Run End Time 
2010-03-08 04:58:43 AM GMT 
     Instrument Type 
sds7500fast 
     Passive Reference 
ROX 
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Well 
Sample 
Name Sample Color Target Name Target Color Task Quantity 
 A1 
  
Line 1 79 RGB(244,165,230) NTC 
  A2 
  
Line 1 79 RGB(244,165,230) NTC 
  A3 
  
Line 1 79 RGB(244,165,230) NTC 
  A4 
  
Line 1 79 RGB(244,165,230) STANDARD 0.25 
 A5 
  
Line 1 79 RGB(244,165,230) STANDARD 0.25 
 A6 
  
Line 1 79 RGB(244,165,230) STANDARD 0.25 
 A7 
  
Line 1 79 RGB(244,165,230) STANDARD 0.0625 
 A8 
  
Line 1 79 RGB(244,165,230) STANDARD 0.0625 
 A9 
  
Line 1 79 RGB(244,165,230) STANDARD 0.0625 
 A10 
  
Line 1 79 RGB(244,165,230) STANDARD 0.015625 
 A11 
  
Line 1 79 RGB(244,165,230) STANDARD 0.015625 
 
   
7-134 
 
A12 
  
Line 1 79 RGB(244,165,230) STANDARD 0.015625 
 B1 
  
Line 1 79 RGB(244,165,230) STANDARD 0.0039063 
 B2 
  
Line 1 79 RGB(244,165,230) STANDARD 0.0039063 
 B3 
  
Line 1 79 RGB(244,165,230) STANDARD 0.0039063 
 B4 
  
Line 1 79 RGB(244,165,230) STANDARD 0.0009766 
 B5 
  
Line 1 79 RGB(244,165,230) STANDARD 0.0009766 
 B6 
  
Line 1 79 RGB(244,165,230) STANDARD 0.0009766 
 B7 Sample 1 RGB(132,193,241) Line 1 79 RGB(244,165,230) UNKNOWN 
  B8 Sample 1 RGB(132,193,241) Line 1 79 RGB(244,165,230) UNKNOWN 
  B9 Sample 1 RGB(132,193,241) Line 1 79 RGB(244,165,230) UNKNOWN 
  B10 Sample 2 RGB(168,255,222) Line 1 79 RGB(244,165,230) UNKNOWN 
  B11 Sample 2 RGB(168,255,222) Line 1 79 RGB(244,165,230) UNKNOWN 
  B12 Sample 2 RGB(168,255,222) Line 1 79 RGB(244,165,230) UNKNOWN 
  
   
7-135 
 
C1 Sample 3 RGB(223,221,142) Line 1 79 RGB(244,165,230) UNKNOWN 
  C2 Sample 3 RGB(223,221,142) Line 1 79 RGB(244,165,230) UNKNOWN 
  C3 Sample 3 RGB(223,221,142) Line 1 79 RGB(244,165,230) UNKNOWN 
  C4 Sample 4 RGB(247,255,168) Line 1 79 RGB(244,165,230) UNKNOWN 
  C5 Sample 4 RGB(247,255,168) Line 1 79 RGB(244,165,230) UNKNOWN 
  C6 Sample 4 RGB(247,255,168) Line 1 79 RGB(244,165,230) UNKNOWN 
  C7 Sample 5 RGB(180,255,0) Line 1 79 RGB(244,165,230) UNKNOWN 
  C8 Sample 5 RGB(180,255,0) Line 1 79 RGB(244,165,230) UNKNOWN 
  C9 Sample 5 RGB(180,255,0) Line 1 79 RGB(244,165,230) UNKNOWN 
  C10 Sample 6 RGB(255,204,153) Line 1 79 RGB(244,165,230) UNKNOWN 
  C11 Sample 6 RGB(255,204,153) Line 1 79 RGB(244,165,230) UNKNOWN 
  C12 Sample 6 RGB(255,204,153) Line 1 79 RGB(244,165,230) UNKNOWN 
  D1 Sample 7 RGB(253,138,88) Line 1 79 RGB(244,165,230) UNKNOWN 
  
   
7-136 
 
D2 Sample 7 RGB(253,138,88) Line 1 79 RGB(244,165,230) UNKNOWN 
  D3 Sample 7 RGB(253,138,88) Line 1 79 RGB(244,165,230) UNKNOWN 
  D4 Sample 8 RGB(213,244,165) Line 1 79 RGB(244,165,230) UNKNOWN 
  D5 Sample 8 RGB(213,244,165) Line 1 79 RGB(244,165,230) UNKNOWN 
  D6 Sample 8 RGB(213,244,165) Line 1 79 RGB(244,165,230) UNKNOWN 
  D7 Sample 9 RGB(96,255,160) Line 1 79 RGB(244,165,230) UNKNOWN 
  D8 Sample 9 RGB(96,255,160) Line 1 79 RGB(244,165,230) UNKNOWN 
  D9 Sample 9 RGB(96,255,160) Line 1 79 RGB(244,165,230) UNKNOWN 
  D10 Sample 10 RGB(132,193,241) Line 1 79 RGB(244,165,230) UNKNOWN 
  D11 Sample 10 RGB(132,193,241) Line 1 79 RGB(244,165,230) UNKNOWN 
  D12 Sample 10 RGB(132,193,241) Line 1 79 RGB(244,165,230) UNKNOWN 
  E1 Sample 11 RGB(168,255,222) Line 1 79 RGB(244,165,230) UNKNOWN 
  E2 Sample 11 RGB(168,255,222) Line 1 79 RGB(244,165,230) UNKNOWN 
  
   
7-137 
 
E3 Sample 11 RGB(168,255,222) Line 1 79 RGB(244,165,230) UNKNOWN 
  E4 Sample 12 RGB(223,221,142) Line 1 79 RGB(244,165,230) UNKNOWN 
  E5 Sample 12 RGB(223,221,142) Line 1 79 RGB(244,165,230) UNKNOWN 
  E6 Sample 12 RGB(223,221,142) Line 1 79 RGB(244,165,230) UNKNOWN 
  E7 Sample 13 RGB(247,255,168) Line 1 79 RGB(244,165,230) UNKNOWN 
  E8 Sample 13 RGB(247,255,168) Line 1 79 RGB(244,165,230) UNKNOWN 
  E9 Sample 13 RGB(247,255,168) Line 1 79 RGB(244,165,230) UNKNOWN 
  E10 Sample 14 RGB(180,255,0) Line 1 79 RGB(244,165,230) UNKNOWN 
  E11 Sample 14 RGB(180,255,0) Line 1 79 RGB(244,165,230) UNKNOWN 
  E12 Sample 14 RGB(180,255,0) Line 1 79 RGB(244,165,230) UNKNOWN 
  F1 Sample 15 RGB(255,204,153) Line 1 79 RGB(244,165,230) UNKNOWN 
  F2 Sample 15 RGB(255,204,153) Line 1 79 RGB(244,165,230) UNKNOWN 
  F3 Sample 15 RGB(255,204,153) Line 1 79 RGB(244,165,230) UNKNOWN 
  
   
7-138 
 
F4 Sample 16 RGB(253,138,88) Line 1 79 RGB(244,165,230) UNKNOWN 
  F5 Sample 16 RGB(253,138,88) Line 1 79 RGB(244,165,230) UNKNOWN 
  F6 Sample 16 RGB(253,138,88) Line 1 79 RGB(244,165,230) UNKNOWN 
  F7 Sample 17 RGB(213,244,165) Line 1 79 RGB(244,165,230) UNKNOWN 
  F8 Sample 17 RGB(213,244,165) Line 1 79 RGB(244,165,230) UNKNOWN 
  F9 Sample 17 RGB(213,244,165) Line 1 79 RGB(244,165,230) UNKNOWN 
  F10 Sample 18 RGB(96,255,160) Line 1 79 RGB(244,165,230) UNKNOWN 
  F11 Sample 18 RGB(96,255,160) Line 1 79 RGB(244,165,230) UNKNOWN 
  F12 Sample 18 RGB(96,255,160) Line 1 79 RGB(244,165,230) UNKNOWN 
  G1 Sample 19 RGB(132,193,241) Line 1 79 RGB(244,165,230) UNKNOWN 
  G2 Sample 19 RGB(132,193,241) Line 1 79 RGB(244,165,230) UNKNOWN 
  G3 Sample 19 RGB(132,193,241) Line 1 79 RGB(244,165,230) UNKNOWN 
  G4 Sample 20 RGB(168,255,222) Line 1 79 RGB(244,165,230) UNKNOWN 
  
   
7-139 
 
G5 Sample 20 RGB(168,255,222) Line 1 79 RGB(244,165,230) UNKNOWN 
  G6 Sample 20 RGB(168,255,222) Line 1 79 RGB(244,165,230) UNKNOWN 
  G7 Sample 21 RGB(223,221,142) Line 1 79 RGB(244,165,230) UNKNOWN 
  G8 Sample 21 RGB(223,221,142) Line 1 79 RGB(244,165,230) UNKNOWN 
  G9 Sample 21 RGB(223,221,142) Line 1 79 RGB(244,165,230) UNKNOWN 
  G10 Sample 22 RGB(247,255,168) Line 1 79 RGB(244,165,230) UNKNOWN 
  G11 Sample 22 RGB(247,255,168) Line 1 79 RGB(244,165,230) UNKNOWN 
  G12 Sample 22 RGB(247,255,168) Line 1 79 RGB(244,165,230) UNKNOWN 
  H1 Sample 23 RGB(180,255,0) Line 1 79 RGB(244,165,230) UNKNOWN 
  H2 Sample 23 RGB(180,255,0) Line 1 79 RGB(244,165,230) UNKNOWN 
  H3 Sample 23 RGB(180,255,0) Line 1 79 RGB(244,165,230) UNKNOWN 
  H4 Sample 24 RGB(255,204,153) Line 1 79 RGB(244,165,230) UNKNOWN 
  H5 Sample 24 RGB(255,204,153) Line 1 79 RGB(244,165,230) UNKNOWN 
  
   
7-140 
 
H6 Sample 24 RGB(255,204,153) Line 1 79 RGB(244,165,230) UNKNOWN 
  H7 Sample 25 RGB(253,138,88) Line 1 79 RGB(244,165,230) UNKNOWN 
  H8 Sample 25 RGB(253,138,88) Line 1 79 RGB(244,165,230) UNKNOWN 
  H9 Sample 25 RGB(253,138,88) Line 1 79 RGB(244,165,230) UNKNOWN 
  H10 Sample 26 RGB(213,244,165) Line 1 79 RGB(244,165,230) UNKNOWN 
  H11 Sample 26 RGB(213,244,165) Line 1 79 RGB(244,165,230) UNKNOWN 
  H12 Sample 26 RGB(213,244,165) Line 1 79 RGB(244,165,230) UNKNOWN 
   
 
 
 
 
   
7-141 
 
Raw data - results Line 1 79bp 
 
Block Type 
96fast 
                Chemistry 
SYBR_GREEN 
               Experiment File Name 
C:\Applied Biosystems\7500\experiments\experiments\Line 1 79.eds 
           Experiment Run End Time 
2010-03-08 04:58:43 AM GMT 
              Instrument Type 
sds7500fast 
               Passive 
Reference 
ROX 
                
   
7-142 
 
Well 
Sample 
Name 
Target 
Name Task Reporter Cт Cт Mean Cт SD Quantity 
Quantity 
Mean Quantity SD 
Automatic 
Ct 
Threshold 
Ct 
Threshold 
Automatic 
Baseline 
Baseline 
Start 
Baseline 
End Tm1 
A1 
 
Line 1 
79 NTC SYBR Undetermined 
     
TRUE 0.035783 TRUE 3 29 71.80394 
A2 
 
Line 1 
79 NTC SYBR Undetermined 
     
TRUE 0.035783 TRUE 3 29 71.6244 
A3 
 
Line 1 
79 NTC SYBR Undetermined 
     
TRUE 0.035783 TRUE 3 29 71.6244 
A4 
 
Line 1 
79 STANDARD SYBR 16.56781197 16.62403 0.13666 0.25 
  
TRUE 0.035783 TRUE 3 14 70.18819 
A5 
 
Line 1 
79 STANDARD SYBR 16.77983665 16.62403 0.13666 0.25 
  
TRUE 0.035783 TRUE 3 14 70.18819 
A6 
 
Line 1 
79 STANDARD SYBR 16.52445221 16.62403 0.13666 0.25 
  
TRUE 0.035783 TRUE 3 14 70.36771 
A7 
 
Line 1 
79 STANDARD SYBR 18.64361763 18.71006 0.057687 0.0625 
  
TRUE 0.035783 TRUE 3 16 70.36771 
A8 
 
Line 1 
79 STANDARD SYBR 18.73918533 18.71006 0.057687 0.0625 
  
TRUE 0.035783 TRUE 3 16 70.36771 
   
7-143 
 
A9 
 
Line 1 
79 STANDARD SYBR 18.7473793 18.71006 0.057687 0.0625 
  
TRUE 0.035783 TRUE 3 16 70.18819 
A10 
 
Line 1 
79 STANDARD SYBR 20.71775818 20.80297 0.077126 0.015625 
  
TRUE 0.035783 TRUE 3 18 70.00866 
A11 
 
Line 1 
79 STANDARD SYBR 20.86799622 20.80297 0.077126 0.015625 
  
TRUE 0.035783 TRUE 3 18 70.00866 
A12 
 
Line 1 
79 STANDARD SYBR 20.82315445 20.80297 0.077126 0.015625 
  
TRUE 0.035783 TRUE 3 18 70.00866 
B1 
 
Line 1 
79 STANDARD SYBR 22.94385529 22.85642 0.078897 0.003906 
  
TRUE 0.035783 TRUE 3 21 69.82913 
B2 
 
Line 1 
79 STANDARD SYBR 22.79053688 22.85642 0.078897 0.003906 
  
TRUE 0.035783 TRUE 3 20 70.00866 
B3 
 
Line 1 
79 STANDARD SYBR 22.83488083 22.85642 0.078897 0.003906 
  
TRUE 0.035783 TRUE 3 20 70.18819 
B4 
 
Line 1 
79 STANDARD SYBR 24.94140053 24.93026 0.009655 0.000977 
  
TRUE 0.035783 TRUE 3 22 70.18819 
B5 
 
Line 1 
79 STANDARD SYBR 24.92507553 24.93026 0.009655 0.000977 
  
TRUE 0.035783 TRUE 3 22 70.18819 
                 
   
7-144 
 
B6 
 
Line 1 
79 STANDARD SYBR 24.92430687 24.93026 0.009655 0.000977 
  
TRUE 0.035783 TRUE 3 23 70.36771 
B7 
Sample 
1 
Line 1 
79 UNKNOWN SYBR 21.09013176 21.09132 0.007957 0.012741 0.012731317 6.76101E-05 TRUE 0.035783 TRUE 3 19 70.36771 
B8 
Sample 
1 
Line 1 
79 UNKNOWN SYBR 21.09980583 21.09132 0.007957 0.012659 0.012731317 6.76101E-05 TRUE 0.035783 TRUE 3 18 70.18819 
B9 
Sample 
1 
Line 1 
79 UNKNOWN SYBR 21.08402634 21.09132 0.007957 0.012793 0.012731317 6.76101E-05 TRUE 0.035783 TRUE 3 19 70.18819 
B10 
Sample 
2 
Line 1 
79 UNKNOWN SYBR 21.11586952 21.23754 0.197495 0.012524 0.011612135 0.001469633 TRUE 0.035783 TRUE 3 19 70.18819 
B11 
Sample 
2 
Line 1 
79 UNKNOWN SYBR 21.13134193 21.23754 0.197495 0.012395 0.011612135 0.001469633 TRUE 0.035783 TRUE 3 18 70.00866 
B12 
Sample 
2 
Line 1 
79 UNKNOWN SYBR 21.46541405 21.23754 0.197495 0.009917 0.011612135 0.001469633 TRUE 0.035783 TRUE 3 19 69.82913 
C1 
Sample 
3 
Line 1 
79 UNKNOWN SYBR 21.10075378 21.07293 0.128714 0.012651 0.012920561 0.001124214 TRUE 0.035783 TRUE 3 19 70.00866 
C2 
Sample 
3 
Line 1 
79 UNKNOWN SYBR 21.18545914 21.07293 0.128714 0.011955 0.012920561 0.001124214 TRUE 0.035783 TRUE 3 19 70.00866 
                 
   
7-145 
 
C3 
Sample 
3 
Line 1 
79 UNKNOWN SYBR 20.93258095 21.07293 0.128714 0.014155 0.012920561 0.001124214 TRUE 0.035783 TRUE 3 19 70.18819 
C4 
Sample 
4 
Line 1 
79 UNKNOWN SYBR 22.65699768 22.74297 0.093927 0.004475 0.00423065 0.000263387 TRUE 0.035783 TRUE 3 20 70.36771 
C5 
Sample 
4 
Line 1 
79 UNKNOWN SYBR 22.72868156 22.74297 0.093927 0.004266 0.00423065 0.000263387 TRUE 0.035783 TRUE 3 20 70.18819 
C6 
Sample 
4 
Line 1 
79 UNKNOWN SYBR 22.84321594 22.74297 0.093927 0.003952 0.00423065 0.000263387 TRUE 0.035783 TRUE 3 20 70.36771 
C7 
Sample 
5 
Line 1 
79 UNKNOWN SYBR 22.53641319 22.53805 0.036776 0.00485 0.00484575 0.000118905 TRUE 0.035783 TRUE 3 20 70.18819 
C8 
Sample 
5 
Line 1 
79 UNKNOWN SYBR 22.50211143 22.53805 0.036776 0.004962 0.00484575 0.000118905 TRUE 0.035783 TRUE 3 20 70.18819 
C9 
Sample 
5 
Line 1 
79 UNKNOWN SYBR 22.57560921 22.53805 0.036776 0.004725 0.00484575 0.000118905 TRUE 0.035783 TRUE 3 20 70.18819 
C10 
Sample 
6 
Line 1 
79 UNKNOWN SYBR 21.93924141 22.03871 0.08617 0.007227 0.006769878 0.00039581 TRUE 0.035783 TRUE 3 19 70.18819 
C11 
Sample 
6 
Line 1 
79 UNKNOWN SYBR 22.09057999 22.03871 0.08617 0.006532 0.006769878 0.00039581 TRUE 0.035783 TRUE 3 20 70.00866 
                 
   
7-146 
 
C12 
Sample 
6 
Line 1 
79 UNKNOWN SYBR 22.08631134 22.03871 0.08617 0.006551 0.006769878 0.00039581 TRUE 0.035783 TRUE 3 20 70.00866 
D1 
Sample 
7 
Line 1 
79 UNKNOWN SYBR 22.06984711 22.14585 0.065967 0.006623 0.006299497 0.000280888 TRUE 0.035783 TRUE 3 19 70.00866 
D2 
Sample 
7 
Line 1 
79 UNKNOWN SYBR 22.17944908 22.14585 0.065967 0.006156 0.006299497 0.000280888 TRUE 0.035783 TRUE 3 20 70.18819 
D3 
Sample 
7 
Line 1 
79 UNKNOWN SYBR 22.1882534 22.14585 0.065967 0.00612 0.006299497 0.000280888 TRUE 0.035783 TRUE 3 20 70.18819 
D4 
Sample 
8 
Line 1 
79 UNKNOWN SYBR 22.7189579 22.88522 0.177087 0.004293 0.003860029 0.000451203 TRUE 0.035783 TRUE 3 20 70.18819 
D5 
Sample 
8 
Line 1 
79 UNKNOWN SYBR 23.07144165 22.88522 0.177087 0.003393 0.003860029 0.000451203 TRUE 0.035783 TRUE 3 21 70.18819 
D6 
Sample 
8 
Line 1 
79 UNKNOWN SYBR 22.86526489 22.88522 0.177087 0.003894 0.003860029 0.000451203 TRUE 0.035783 TRUE 3 21 70.36771 
D7 
Sample 
9 
Line 1 
79 UNKNOWN SYBR 21.90338516 21.92776 0.06958 0.007402 0.007287627 0.000334898 TRUE 0.035783 TRUE 3 19 70.36771 
D8 
Sample 
9 
Line 1 
79 UNKNOWN SYBR 22.00624657 21.92776 0.06958 0.006911 0.007287627 0.000334898 TRUE 0.035783 TRUE 3 20 70.36771 
                 
   
7-147 
 
D9 
Sample 
9 
Line 1 
79 UNKNOWN SYBR 21.87364578 21.92776 0.06958 0.00755 0.007287627 0.000334898 TRUE 0.035783 TRUE 3 19 70.18819 
D10 
Sample 
10 
Line 1 
79 UNKNOWN SYBR 20.88681412 20.96103 0.088881 0.014594 0.013904788 0.000815655 TRUE 0.035783 TRUE 3 18 70.18819 
D11 
Sample 
10 
Line 1 
79 UNKNOWN SYBR 20.93674278 20.96103 0.088881 0.014116 0.013904788 0.000815655 TRUE 0.035783 TRUE 3 18 70.18819 
D12 
Sample 
10 
Line 1 
79 UNKNOWN SYBR 21.05952835 20.96103 0.088881 0.013004 0.013904788 0.000815655 TRUE 0.035783 TRUE 3 19 70.00866 
E1 
Sample 
11 
Line 1 
79 UNKNOWN SYBR 22.44207191 22.4341 0.007133 0.005165 0.005193074 2.47115E-05 TRUE 0.035783 TRUE 3 20 70.00866 
E2 
Sample 
11 
Line 1 
79 UNKNOWN SYBR 22.42832375 22.4341 0.007133 0.005213 0.005193074 2.47115E-05 TRUE 0.035783 TRUE 3 20 70.18819 
E3 
Sample 
11 
Line 1 
79 UNKNOWN SYBR 22.43190193 22.4341 0.007133 0.005201 0.005193074 2.47115E-05 TRUE 0.035783 TRUE 3 20 70.18819 
E4 
Sample 
12 
Line 1 
79 UNKNOWN SYBR 22.91010857 22.9426 0.044894 0.003779 0.003698872 0.000110023 TRUE 0.035783 TRUE 3 20 70.18819 
E5 
Sample 
12 
Line 1 
79 UNKNOWN SYBR 22.99382782 22.9426 0.044894 0.003573 0.003698872 0.000110023 TRUE 0.035783 TRUE 3 21 70.18819 
                 
   
7-148 
 
E6 
Sample 
12 
Line 1 
79 UNKNOWN SYBR 22.92386436 22.9426 0.044894 0.003744 0.003698872 0.000110023 TRUE 0.035783 TRUE 3 20 70.36771 
E7 
Sample 
13 
Line 1 
79 UNKNOWN SYBR 21.27283478 21.15307 0.191925 0.011278 0.01228549 0.001627657 TRUE 0.035783 TRUE 3 19 70.36771 
E8 
Sample 
13 
Line 1 
79 UNKNOWN SYBR 21.25467682 21.15307 0.191925 0.011415 0.01228549 0.001627657 TRUE 0.035783 TRUE 3 19 70.36771 
E9 
Sample 
13 
Line 1 
79 UNKNOWN SYBR 20.93170357 21.15307 0.191925 0.014163 0.01228549 0.001627657 TRUE 0.035783 TRUE 3 18 70.36771 
E10 
Sample 
14 
Line 1 
79 UNKNOWN SYBR 22.49219704 22.53241 0.082388 0.004995 0.004867907 0.000263599 TRUE 0.035783 TRUE 3 20 70.18819 
E11 
Sample 
14 
Line 1 
79 UNKNOWN SYBR 22.47784615 22.53241 0.082388 0.005044 0.004867907 0.000263599 TRUE 0.035783 TRUE 3 20 70.18819 
E12 
Sample 
14 
Line 1 
79 UNKNOWN SYBR 22.6271801 22.53241 0.082388 0.004565 0.004867907 0.000263599 TRUE 0.035783 TRUE 3 20 70.00866 
F1 
Sample 
15 
Line 1 
79 UNKNOWN SYBR 21.77561569 21.74323 0.061909 0.008061 0.008242189 0.000344685 TRUE 0.035783 TRUE 3 19 69.82913 
F2 
Sample 
15 
Line 1 
79 UNKNOWN SYBR 21.78224182 21.74323 0.061909 0.008026 0.008242189 0.000344685 TRUE 0.035783 TRUE 3 19 70.00866 
                 
   
7-149 
 
F3 
Sample 
15 
Line 1 
79 UNKNOWN SYBR 21.67185211 21.74323 0.061909 0.00864 0.008242189 0.000344685 TRUE 0.035783 TRUE 3 19 70.18819 
F4 
Sample 
16 
Line 1 
79 UNKNOWN SYBR 21.57563591 21.65517 0.08086 0.009213 0.008744922 0.000471443 TRUE 0.035783 TRUE 3 19 70.18819 
F5 
Sample 
16 
Line 1 
79 UNKNOWN SYBR 21.65259171 21.65517 0.08086 0.008752 0.008744922 0.000471443 TRUE 0.035783 TRUE 3 19 70.18819 
F6 
Sample 
16 
Line 1 
79 UNKNOWN SYBR 21.73729324 21.65517 0.08086 0.00827 0.008744922 0.000471443 TRUE 0.035783 TRUE 3 19 70.18819 
F7 
Sample 
17 
Line 1 
79 UNKNOWN SYBR 22.34988594 22.39887 0.059147 0.005493 0.005319388 0.00020845 TRUE 0.035783 TRUE 3 20 70.18819 
F8 
Sample 
17 
Line 1 
79 UNKNOWN SYBR 22.38216019 22.39887 0.059147 0.005376 0.005319388 0.00020845 TRUE 0.035783 TRUE 3 20 70.18819 
F9 
Sample 
17 
Line 1 
79 UNKNOWN SYBR 22.46458244 22.39887 0.059147 0.005088 0.005319388 0.00020845 TRUE 0.035783 TRUE 3 20 70.18819 
F10 
Sample 
18 
Line 1 
79 UNKNOWN SYBR 22.10458755 22.25439 0.130002 0.006471 0.005870172 0.000521499 TRUE 0.035783 TRUE 3 19 70.18819 
F11 
Sample 
18 
Line 1 
79 UNKNOWN SYBR 22.3209362 22.25439 0.130002 0.005601 0.005870172 0.000521499 TRUE 0.035783 TRUE 3 20 70.18819 
                 
   
7-150 
 
F12 
Sample 
18 
Line 1 
79 UNKNOWN SYBR 22.33764648 22.25439 0.130002 0.005539 0.005870172 0.000521499 TRUE 0.035783 TRUE 3 20 70.00866 
G1 
Sample 
19 
Line 1 
79 UNKNOWN SYBR 22.1571579 22.14281 0.027467 0.006248 0.006308919 0.000116324 TRUE 0.035783 TRUE 3 20 69.82913 
G2 
Sample 
19 
Line 1 
79 UNKNOWN SYBR 22.11113358 22.14281 0.027467 0.006443 0.006308919 0.000116324 TRUE 0.035783 TRUE 3 20 70.00866 
G3 
Sample 
19 
Line 1 
79 UNKNOWN SYBR 22.16012001 22.14281 0.027467 0.006236 0.006308919 0.000116324 TRUE 0.035783 TRUE 3 20 70.00866 
G4 
Sample 
20 
Line 1 
79 UNKNOWN SYBR 20.70654106 20.77372 0.058243 0.016461 0.01574721 0.000619154 TRUE 0.035783 TRUE 3 18 70.00866 
G5 
Sample 
20 
Line 1 
79 UNKNOWN SYBR 20.80999947 20.77372 0.058243 0.015362 0.01574721 0.000619154 TRUE 0.035783 TRUE 3 18 70.00866 
G6 
Sample 
20 
Line 1 
79 UNKNOWN SYBR 20.80462646 20.77372 0.058243 0.015418 0.01574721 0.000619154 TRUE 0.035783 TRUE 3 18 70.18819 
G7 
Sample 
21 
Line 1 
79 UNKNOWN SYBR 22.96528816 23.01903 0.05269 0.003642 0.003515227 0.000123808 TRUE 0.035783 TRUE 3 20 70.18819 
G8 
Sample 
21 
Line 1 
79 UNKNOWN SYBR 23.02118683 23.01903 0.05269 0.003509 0.003515227 0.000123808 TRUE 0.035783 TRUE 3 20 70.18819 
                 
   
7-151 
 
G9 
Sample 
21 
Line 1 
79 UNKNOWN SYBR 23.07060242 23.01903 0.05269 0.003395 0.003515227 0.000123808 TRUE 0.035783 TRUE 3 21 70.00866 
G10 
Sample 
22 
Line 1 
79 UNKNOWN SYBR 22.87696838 22.88319 0.023635 0.003863 0.00384775 6.05555E-05 TRUE 0.035783 TRUE 3 20 70.18819 
G11 
Sample 
22 
Line 1 
79 UNKNOWN SYBR 22.86328697 22.88319 0.023635 0.003899 0.00384775 6.05555E-05 TRUE 0.035783 TRUE 3 20 70.00866 
G12 
Sample 
22 
Line 1 
79 UNKNOWN SYBR 22.9093132 22.88319 0.023635 0.003781 0.00384775 6.05555E-05 TRUE 0.035783 TRUE 3 20 70.00866 
H1 
Sample 
23 
Line 1 
79 UNKNOWN SYBR 19.9601059 20.09171 0.134209 0.027099 0.02488552 0.002222565 TRUE 0.035783 TRUE 3 17 69.82913 
H2 
Sample 
23 
Line 1 
79 UNKNOWN SYBR 20.08666039 20.09171 0.134209 0.024903 0.02488552 0.002222565 TRUE 0.035783 TRUE 3 17 69.82913 
H3 
Sample 
23 
Line 1 
79 UNKNOWN SYBR 20.2283802 20.09171 0.134209 0.022654 0.02488552 0.002222565 TRUE 0.035783 TRUE 3 17 69.82913 
H4 
Sample 
24 
Line 1 
79 UNKNOWN SYBR 21.16566277 21.32312 0.165309 0.012115 0.010949518 0.001198132 TRUE 0.035783 TRUE 3 19 69.82913 
H5 
Sample 
24 
Line 1 
79 UNKNOWN SYBR 21.30839348 21.32312 0.165309 0.011013 0.010949518 0.001198132 TRUE 0.035783 TRUE 3 19 70.00866 
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H6 
Sample 
24 
Line 1 
79 UNKNOWN SYBR 21.49529648 21.32312 0.165309 0.009721 0.010949518 0.001198132 TRUE 0.035783 TRUE 3 19 70.00866 
H7 
Sample 
25 
Line 1 
79 UNKNOWN SYBR 22.63315392 22.65711 0.024832 0.004547 0.004474884 7.41448E-05 TRUE 0.035783 TRUE 3 20 70.00866 
H8 
Sample 
25 
Line 1 
79 UNKNOWN SYBR 22.65543175 22.65711 0.024832 0.004479 0.004474884 7.41448E-05 TRUE 0.035783 TRUE 3 20 70.00866 
H9 
Sample 
25 
Line 1 
79 UNKNOWN SYBR 22.68273354 22.65711 0.024832 0.004399 0.004474884 7.41448E-05 TRUE 0.035783 TRUE 3 20 70.00866 
H10 
Sample 
26 
Line 1 
79 UNKNOWN SYBR 23.22262764 23.24241 0.15147 0.003067 0.003037081 0.000303832 TRUE 0.035783 TRUE 3 20 70.00866 
H11 
Sample 
26 
Line 1 
79 UNKNOWN SYBR 23.4027977 23.24241 0.15147 0.002719 0.003037081 0.000303832 TRUE 0.035783 TRUE 3 21 69.82913 
H12 
Sample 
26 
Line 1 
79 UNKNOWN SYBR 23.10180092 23.24241 0.15147 0.003325 0.003037081 0.000303832 TRUE 0.035783 TRUE 3 20 69.82913 
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